A systematic review of metabolite biomarkers of schizophrenia
Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more objective biological measurement and medical diagnostic tests are not presently available. The use of metabolomics in the discovery of disease biomar...
Saved in:
| Published in | Schizophrenia research Vol. 195; pp. 32 - 50 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
Netherlands
Elsevier B.V
01.05.2018
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0920-9964 1573-2509 1573-2509 |
| DOI | 10.1016/j.schres.2017.09.021 |
Cover
| Abstract | Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more objective biological measurement and medical diagnostic tests are not presently available. The use of metabolomics in the discovery of disease biomarkers has grown in recent years. Metabolomic methods could aid in the discovery of diagnostic biomarkers of schizophrenia. This systematic review focuses on biofluid metabolites associated with schizophrenia. A systematic search of Web of Science and Ovid Medline databases was conducted and 63 studies investigating metabolite biomarkers of schizophrenia were included. A review of these studies revealed several potential metabolite signatures of schizophrenia including reduced levels of essential polyunsaturated fatty acids (EPUFAs), vitamin E and creatinine; and elevated levels of lipid peroxidation metabolites and glutamate. Further research is needed to validate these biomarkers and would benefit from large cohort studies and more homogeneous and well-defined subject groups. |
|---|---|
| AbstractList | Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more objective biological measurement and medical diagnostic tests are not presently available. The use of metabolomics in the discovery of disease biomarkers has grown in recent years. Metabolomic methods could aid in the discovery of diagnostic biomarkers of schizophrenia. This systematic review focuses on biofluid metabolites associated with schizophrenia. A systematic search of Web of Science and Ovid Medline databases was conducted and 63 studies investigating metabolite biomarkers of schizophrenia were included. A review of these studies revealed several potential metabolite signatures of schizophrenia including reduced levels of essential polyunsaturated fatty acids (EPUFAs), vitamin E and creatinine; and elevated levels of lipid peroxidation metabolites and glutamate. Further research is needed to validate these biomarkers and would benefit from large cohort studies and more homogeneous and well-defined subject groups. AbstractCurrent diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more objective biological measurement and medical diagnostic tests are not presently available. The use of metabolomics in the discovery of disease biomarkers has grown in recent years. Metabolomic methods could aid in the discovery of diagnostic biomarkers of schizophrenia. This systematic review focuses on biofluid metabolites associated with schizophrenia. A systematic search of Web of Science and Ovid Medline databases was conducted and 63 studies investigating metabolite biomarkers of schizophrenia were included. A review of these studies revealed several potential metabolite signatures of schizophrenia including reduced levels of essential polyunsaturated fatty acids (EPUFAs), vitamin E and creatinine; and elevated levels of lipid peroxidation metabolites and glutamate. Further research is needed to validate these biomarkers and would benefit from large cohort studies and more homogeneous and well-defined subject groups. Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more objective biological measurement and medical diagnostic tests are not presently available. The use of metabolomics in the discovery of disease biomarkers has grown in recent years. Metabolomic methods could aid in the discovery of diagnostic biomarkers of schizophrenia. This systematic review focuses on biofluid metabolites associated with schizophrenia. A systematic search of Web of Science and Ovid Medline databases was conducted and 63 studies investigating metabolite biomarkers of schizophrenia were included. A review of these studies revealed several potential metabolite signatures of schizophrenia including reduced levels of essential polyunsaturated fatty acids (EPUFAs), vitamin E and creatinine; and elevated levels of lipid peroxidation metabolites and glutamate. Further research is needed to validate these biomarkers and would benefit from large cohort studies and more homogeneous and well-defined subject groups.Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more objective biological measurement and medical diagnostic tests are not presently available. The use of metabolomics in the discovery of disease biomarkers has grown in recent years. Metabolomic methods could aid in the discovery of diagnostic biomarkers of schizophrenia. This systematic review focuses on biofluid metabolites associated with schizophrenia. A systematic search of Web of Science and Ovid Medline databases was conducted and 63 studies investigating metabolite biomarkers of schizophrenia were included. A review of these studies revealed several potential metabolite signatures of schizophrenia including reduced levels of essential polyunsaturated fatty acids (EPUFAs), vitamin E and creatinine; and elevated levels of lipid peroxidation metabolites and glutamate. Further research is needed to validate these biomarkers and would benefit from large cohort studies and more homogeneous and well-defined subject groups. |
| Author | O'Gorman, Aoife Cotter, David R. Brennan, Lorraine Davison, Jennifer |
| Author_xml | – sequence: 1 givenname: Jennifer surname: Davison fullname: Davison, Jennifer organization: RCSI Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre Beaumont Hospital, Dublin 9, Ireland – sequence: 2 givenname: Aoife surname: O'Gorman fullname: O'Gorman, Aoife organization: RCSI Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre Beaumont Hospital, Dublin 9, Ireland – sequence: 3 givenname: Lorraine surname: Brennan fullname: Brennan, Lorraine organization: Institute of Food & Health, UCD School of Agriculture and Food Science, University College Dublin, Dublin 4, Ireland – sequence: 4 givenname: David R. orcidid: 0000-0003-4308-0648 surname: Cotter fullname: Cotter, David R. email: drcotter@rcsi.ie organization: RCSI Psychiatry, Royal College of Surgeons in Ireland, Education and Research Centre Beaumont Hospital, Dublin 9, Ireland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28947341$$D View this record in MEDLINE/PubMed |
| BookMark | eNqVkktv1TAQhS1URG8L_wChLNkkjF9JjKBSVfGSKrEA1pbjTIRvE_tiJ1SXX4-jFBZIqLCwZuFzzoy-mTNy4oNHQp5SqCjQ-sW-SvZrxFQxoE0FqgJGH5AdlQ0vmQR1QnagGJRK1eKUnKW0BwAqoXlETlmrRMMF3ZHXl0U6phknMztbRPzu8LYIQzHhbLowuhmLzoXJxBuMaf3ITd2PcMidvTOPycPBjAmf3NVz8uXtm89X78vrj-8-XF1el1a2bC55p2yHQiqpLJr8hBw6SWvsTC05tCitaCUI2xphDPZ9LQZmGsUpFbUAxc-J3HIXfzDHWzOO-hBdnuqoKegVh97rDYdecWhQOuPIvueb7xDDtwXTrCeXLI6j8RiWpKkSnLVc8SZLn91Jl27C_nf-L1RZ8HIT2BhSijho6-ZMLfg5GjfeN4j4w_yP819sNsxw82piFjn0FnsX0c66D-5_A-zovLNmvMEjpn1Yos-L01QnpkF_Wi9mPRjacJAtrFhe_T3g_v4_AQLP0XE |
| CitedBy_id | crossref_primary_10_3390_molecules28010324 crossref_primary_10_1080_15622975_2020_1805510 crossref_primary_10_1038_s41398_022_02000_1 crossref_primary_10_1038_s41380_022_01591_x crossref_primary_10_3390_ijms242115631 crossref_primary_10_1016_j_schres_2022_02_029 crossref_primary_10_1177_15330338211037821 crossref_primary_10_3389_fpsyt_2022_1025414 crossref_primary_10_3390_molecules28114385 crossref_primary_10_1002_erv_3114 crossref_primary_10_1016_j_schres_2019_07_057 crossref_primary_10_1134_S1819712422010032 crossref_primary_10_3389_fpsyt_2018_00580 crossref_primary_10_1017_S0033291724002228 crossref_primary_10_1186_s12916_022_02261_z crossref_primary_10_1093_schizbullopen_sgaa032 crossref_primary_10_1002_14651858_CD015671 crossref_primary_10_1016_j_neubiorev_2022_104954 crossref_primary_10_1002_ange_202101007 crossref_primary_10_1016_j_trac_2023_117367 crossref_primary_10_1016_j_cca_2021_11_028 crossref_primary_10_3390_ijms24097682 crossref_primary_10_1038_s41598_022_05609_w crossref_primary_10_1038_s41598_023_29117_7 crossref_primary_10_1016_j_bbih_2022_100453 crossref_primary_10_3389_fpsyt_2018_00155 crossref_primary_10_1016_j_jpsychires_2023_04_010 crossref_primary_10_1093_schbul_sbaa087 crossref_primary_10_3389_fpsyt_2022_885904 crossref_primary_10_1016_j_pnpbp_2019_03_010 crossref_primary_10_1016_j_ajp_2021_102566 crossref_primary_10_1007_s00221_022_06495_4 crossref_primary_10_1038_s41380_021_01339_z crossref_primary_10_1002_anie_202101007 crossref_primary_10_3390_ijms23094917 crossref_primary_10_1007_s12035_024_04477_x crossref_primary_10_2174_1381612827666210804110139 crossref_primary_10_1038_s41380_021_01201_2 crossref_primary_10_1016_j_schres_2023_11_014 crossref_primary_10_1016_j_encep_2019_11_009 crossref_primary_10_1093_ijnp_pyad012 crossref_primary_10_1038_s41598_024_83288_5 crossref_primary_10_1016_j_schres_2022_01_024 crossref_primary_10_1016_j_eswa_2022_118236 crossref_primary_10_1186_s12888_024_05660_z crossref_primary_10_1109_JPROC_2019_2908582 crossref_primary_10_1016_j_schres_2019_03_009 crossref_primary_10_3390_brainsci13030426 crossref_primary_10_1016_j_bionps_2021_100045 crossref_primary_10_1016_j_ejpsy_2024_100285 crossref_primary_10_1038_s41398_020_01080_1 crossref_primary_10_1038_s41598_020_71014_w crossref_primary_10_1080_15622975_2019_1615639 crossref_primary_10_1038_s43856_024_00467_1 crossref_primary_10_1515_mr_2022_0009 crossref_primary_10_3390_ijms21134784 crossref_primary_10_1038_s41598_020_78559_w crossref_primary_10_1016_j_bpsgos_2023_07_004 crossref_primary_10_1002_npr2_12223 crossref_primary_10_1007_s11011_022_01147_6 crossref_primary_10_1016_j_psychres_2023_115070 crossref_primary_10_1016_j_schres_2025_03_016 crossref_primary_10_1002_brb3_3002 crossref_primary_10_1016_j_clinbiochem_2019_12_003 crossref_primary_10_1016_j_jconrel_2024_05_029 crossref_primary_10_1016_j_micpath_2020_104587 crossref_primary_10_1038_s41537_024_00496_8 crossref_primary_10_1016_j_pnpbp_2021_110348 crossref_primary_10_1038_s41380_019_0374_8 crossref_primary_10_1186_s12974_021_02260_6 crossref_primary_10_1186_s12888_020_02499_y crossref_primary_10_3390_medicina59020413 crossref_primary_10_3389_fpsyt_2020_00496 crossref_primary_10_3389_fpsyt_2021_728986 crossref_primary_10_1002_ajmg_b_32969 crossref_primary_10_3389_fpsyt_2018_00753 crossref_primary_10_1186_s12991_024_00521_1 crossref_primary_10_3389_fimmu_2022_812293 crossref_primary_10_7554_eLife_76391 crossref_primary_10_1111_cns_13895 crossref_primary_10_1111_pcn_12779 crossref_primary_10_1093_schbul_sbaa166 crossref_primary_10_1093_schbul_sbad039 crossref_primary_10_3390_ijms222010917 crossref_primary_10_1038_s41398_023_02626_9 crossref_primary_10_1186_s12888_025_06644_3 crossref_primary_10_1016_j_csbj_2023_07_027 crossref_primary_10_3389_fpsyt_2022_998709 crossref_primary_10_2147_NDT_S236034 crossref_primary_10_3390_biom10010160 crossref_primary_10_1016_j_jprot_2024_105296 crossref_primary_10_1016_j_biopsych_2019_01_018 crossref_primary_10_1093_schbul_sbz067 crossref_primary_10_1080_15622975_2023_2271965 crossref_primary_10_3390_jcm11143964 crossref_primary_10_1093_schbul_sbad026 crossref_primary_10_3390_s24206508 crossref_primary_10_1016_j_psychres_2021_114164 crossref_primary_10_18632_aging_203311 crossref_primary_10_1093_schizbullopen_sgae018 crossref_primary_10_1097_YPG_0000000000000365 crossref_primary_10_1016_j_psychres_2023_115605 crossref_primary_10_1016_j_schres_2023_10_016 crossref_primary_10_1016_j_schres_2022_09_022 crossref_primary_10_1186_s12944_025_02512_x crossref_primary_10_1038_s41380_024_02568_8 crossref_primary_10_3389_fpsyt_2020_00432 crossref_primary_10_1016_j_schres_2018_11_010 |
| Cites_doi | 10.1093/schbul/sbt065 10.1038/mp.2009.33 10.1371/journal.pone.0101652 10.1210/jc.2014-1887 10.1016/j.plefa.2006.11.003 10.2174/1570159X11666131120230309 10.1038/tp.2014.19 10.1016/j.psychres.2015.11.045 10.1097/YCO.0000000000000054 10.1111/eip.12282 10.1158/1055-9965.EPI-12-1236 10.1176/ajp.154.1.69 10.1001/archpsyc.1990.01810190041006 10.1016/j.psyneuen.2013.12.005 10.3389/fnana.2015.00091 10.1038/npp.2011.187 10.1001/jamapsychiatry.2014.243 10.1002/hup.1102 10.1023/A:1015172914991 10.1155/2013/510402 10.1039/C1AN15605E 10.1021/pr800188y 10.1186/gm300 10.2174/2213235X113019990005 10.1001/archpsyc.1980.01780230031004 10.1177/070674370505001109 10.5936/csbj.201301004 10.2174/157015911795596595 10.1371/journal.pmed.1000097 10.1016/j.neubiorev.2013.06.007 10.1016/0006-3223(91)90291-S 10.1007/s13238-015-0185-x 10.1001/archgenpsychiatry.2009.192 10.1159/000228838 10.5498/wjp.v6.i1.102 10.1371/journal.pone.0042165 10.1007/s00213-007-0921-x 10.1176/appi.ajp.162.10.1785 10.1016/j.jsbmb.2012.08.009 10.1016/j.pnpbp.2013.02.007 10.1038/tp.2012.76 10.1016/j.neubiorev.2014.05.010 10.1176/ajp.137.2.174 10.1016/S0893-133X(01)00250-0 10.1016/S0006-3223(02)01443-9 10.1093/schbul/sbt105 10.1176/appi.ajp.2016.15070890 10.1001/archpsyc.1975.01760260127011 10.1093/schbul/sbl049 10.1016/0024-3205(82)90074-1 10.1192/bjp.176.3.290 10.1093/ijnp/pyv096 10.1016/j.psyneuen.2015.10.007 10.1111/j.1601-5215.2006.00170.x 10.1093/schbul/sbv028 10.1192/bjp.143.1.69 10.2217/bmm-2015-0055 10.1371/journal.pone.0068717 10.3109/15622975.2015.1048724 10.1016/j.clinph.2013.05.021 10.1111/bdi.12386 10.1016/S0920-9964(97)00151-5 10.1016/j.jpsychires.2014.10.011 10.1001/archpsyc.1987.01800190020003 10.1159/000213565 10.1016/j.nbd.2009.02.019 10.1002/bms.1200060804 10.1021/pr2006796 10.1038/tp.2016.159 10.1177/0269881114566631 10.1016/0006-3223(86)90283-0 10.1021/pr300459d 10.1192/bjp.181.5.363 10.1111/pcn.12322 10.1016/0022-510X(79)90023-6 10.1016/S0006-3223(02)01397-5 10.1016/S0006-3223(97)00282-5 10.3389/fphys.2014.00150 10.1016/S0920-9964(01)00334-6 10.1159/000115048 10.1016/j.schres.2008.06.005 10.1039/C4MB00157E 10.1016/0006-3223(92)90110-L 10.1016/j.neuint.2010.02.015 10.1016/j.tibtech.2015.09.010 10.1016/j.schres.2015.06.022 10.1016/0920-9964(91)90014-I 10.1016/0920-9964(94)90043-4 10.1186/s12967-015-0540-y 10.1016/j.arcmed.2004.06.002 10.1186/s12888-016-1039-7 10.1021/pr0503782 10.1016/0920-9964(94)90084-1 10.1192/bjp.147.3.276 10.1016/j.pneurobio.2010.09.003 10.1111/j.1600-0447.1982.tb06717.x 10.1016/j.psychres.2006.04.009 10.1080/14789450.2016.1252262 10.1017/S0033291710002023 10.1016/0165-1781(83)90003-3 10.1016/0920-9964(94)00034-6 10.1159/000364828 10.1038/npp.2013.167 10.1016/0006-3223(89)90216-3 10.1186/gm233 10.1038/sj.mp.4002000 10.1038/mp.2011.42 10.1176/ajp.2007.164.7.1072 10.1007/BF00445551 10.1093/schbul/sbu052 10.1176/ajp.135.5.567 10.1002/cbf.940 10.1051/ocl/2015054 10.2174/138161212799316055 10.1111/acps.12388 10.1001/archpsyc.1993.01820200009001 10.1002/hup.2386 10.1038/mp.2011.131 10.1007/s00702-014-1224-0 10.1001/jamapsychiatry.2014.1332 10.1371/journal.pone.0156432 |
| ContentType | Journal Article |
| Copyright | 2017 Copyright © 2017. Published by Elsevier B.V. |
| Copyright_xml | – notice: 2017 – notice: Copyright © 2017. Published by Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
| DOI | 10.1016/j.schres.2017.09.021 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1573-2509 |
| EndPage | 50 |
| ExternalDocumentID | oai:researchrepository.ucd.ie:10197/9339 28947341 10_1016_j_schres_2017_09_021 S0920996417305807 1_s2_0_S0920996417305807 |
| Genre | Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GrantInformation_xml | – fundername: European Research Council grantid: 647783 |
| GroupedDBID | --- --K --M -~X .1- .FO .GJ .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 4H- 53G 5VS 7-5 71M 8P~ 9JM 9JO AABNK AADFP AAEDT AAEDW AAGJA AAGUQ AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AATTM AAWTL AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABFNM ABIVO ABJNI ABMAC ABMZM ABOYX ABWVN ABXDB ACDAQ ACGFS ACHQT ACIEU ACIUM ACLOT ACRLP ACRPL ACVFH ACXNI ADBBV ADCNI ADEZE ADMUD ADNMO AEBSH AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGQPQ AGUBO AGWIK AGYEJ AHHHB AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DU5 EBS EFJIC EFKBS EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HEG HMK HMO HMQ HMW HVGLF HZ~ IHE J1W KOM M29 M2V M39 M3V M41 MO0 MOBAO N9A O-L O9- OAUVE OH0 OKEIE OU- OZT P-8 P-9 P2P PC. Q38 R2- ROL RPZ SAE SCC SDF SDG SDP SEL SES SEW SNS SPCBC SPS SSB SSH SSN SSY SSZ T5K WUQ Z5R ~G- ~HD AACTN AFCTW AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AFYLN AJBFU LCYCR AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 ADTOC UNPAY |
| ID | FETCH-LOGICAL-c582t-3b9cbe45959cea9ce45fb516eba65308e5c48504c8a4aaedd64f2a79311464093 |
| IEDL.DBID | UNPAY |
| ISSN | 0920-9964 1573-2509 |
| IngestDate | Wed Oct 29 11:55:37 EDT 2025 Mon Sep 29 05:15:18 EDT 2025 Mon Jul 21 05:23:41 EDT 2025 Wed Oct 01 04:37:07 EDT 2025 Thu Apr 24 23:00:56 EDT 2025 Fri Feb 23 02:32:21 EST 2024 Sun Feb 23 10:19:48 EST 2025 Tue Oct 14 19:30:58 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | Psychosis Schizophrenia Biomarkers Metabolomics Lipidomics Biofluid |
| Language | English |
| License | Copyright © 2017. Published by Elsevier B.V. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c582t-3b9cbe45959cea9ce45fb516eba65308e5c48504c8a4aaedd64f2a79311464093 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Undefined-4 |
| ORCID | 0000-0003-4308-0648 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=http://hdl.handle.net/10197/9339 |
| PMID | 28947341 |
| PQID | 1943283937 |
| PQPubID | 23479 |
| PageCount | 19 |
| ParticipantIDs | unpaywall_primary_10_1016_j_schres_2017_09_021 proquest_miscellaneous_1943283937 pubmed_primary_28947341 crossref_citationtrail_10_1016_j_schres_2017_09_021 crossref_primary_10_1016_j_schres_2017_09_021 elsevier_sciencedirect_doi_10_1016_j_schres_2017_09_021 elsevier_clinicalkeyesjournals_1_s2_0_S0920996417305807 elsevier_clinicalkey_doi_10_1016_j_schres_2017_09_021 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-05-01 |
| PublicationDateYYYYMMDD | 2018-05-01 |
| PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Schizophrenia research |
| PublicationTitleAlternate | Schizophr Res |
| PublicationYear | 2018 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Peng, Li, Peng (bb0435) 2015; 6 Horrobin, Bennett (bb0200) 1999 Scottish Schizophrenia Research Group (bb0530) 2000; 176 Berger, Faull, Kilkowski, Anderson, Kraemer, Davis, Barchas (bb0055) 1980; 137 Horrobin, Manku, Morse-Fisher, Vaddadi, Courtney, Glen, Glen, Spellman, Bates (bb0205) 1989; 25 Guest, Guest, Martins-de-Souza (bb0180) 2016; 10 Solberg, Bentsen, Refsum, Andreassen (bb0550) 2015; 132 Ballesteros, Summerfelt, Du, Jiang, Chiappelli, Tagamets, O'Donnell, Kochunov, Hong (bb0040) 2013; 124 Liu, Zheng, Liu, Xu, Mu, Guo, Huang, Meng, Xie (bb0305) 2014; 10 Obi, Nwanze (bb0405) 1979; 43 Chan, Cooper, Bahn (bb0110) 2015; 33 Larsen, Melle, Auestad, Haahr, Joa, Johannessen, Opjordsmoen, Rund, Rossberg, Simonsen, Vaglum, Friis, McGlashan (bb0290) 2011; 41 Tsang, Huang, Holmes, Bahn (bb0575) 2006; 5 Mahadik, Mukherjee, Scheffer, Correnti, Mahadik (bb0315) 1998; 43 Kaddurah-Daouk, McEvoy, Baillie, Lee, Yao, Doraiswamy, Krishnan (bb0225) 2007; 12 Walker, Bonsall, Walder (bb0590) 2002; 15 Arvindakshan, Sitasawad, Debsikdar, Ghate, Evans, Horrobin, Bennett, Ranjekar, Mahadik (bb0035) 2003; 53 Focking, Dicker, Lopez, Cannon, Schafer, McGorry, Smesny, Cotter, Amminger (bb0145) 2016; 16 McNamara, Jandacek, Tso, Blom, Welge, Strawn, Adler, Strakowski, DelBello (bb0345) 2016; 10 Cotter, Pariante (bb0130) 2002; 181 Bates, Horrobin, Ells (bb0045) 1991; 6 Liu, Zhang, Du, Fang, Liu, Xu, Zheng, Xu, Cheng, Huang, Bai, Zhao, Qi, Shao, Xie (bb0310) 2015; 13 Jacobsen, Frazier, Malhotra, Karoum, McKenna, Gordon, Hamburger, Lenane, Pickar, Potter, Rapoport (bb0220) 1997; 154 Sabherwal, English, Focking, Cagney, Cotter (bb0495) 2016; 13 McNamara, Welge (bb0340) 2016; 18 Taneli, Pirildar, Akdeniz, Uyanik, Ari (bb0565) 2004; 35 Pickar, Breier, Hsiao, Doran, Wolkowitz, Pato, Konicki, Potter (bb0450) 1990; 47 Perkins, Gu, Boteva, Lieberman (bb0440) 2005; 162 Nakano, Yoshimura, Nakano, Ikenouchi-Sugita, Hori, Umene-Nakano, Ueda, Nakamura (bb0385) 2010; 25 Nyback, Berggren, Hindmarsh, Sedvall, Wiesel (bb0400) 1983; 9 Anand, Sunitha, Khanna (bb0030) 2002; 44 Pickard (bb0455) 2015; 29 Waziri, Wilson, Sherman (bb0605) 1983; 143 Nilsson-Todd, Nordin, Joensson, Skogh, Erhardt (bb0395) 2007; 19 Fukushima, Iizuka, Yokota, Suzuki, Ohno, Kono, Nishikiori, Seki, Ichiba, Watanabe, Hongo, Utsunomiya, Nakatani, Sadamoto, Yoshio (bb0155) 2014; 9 Markianos, Botsis, Arvanitis (bb0325) 1992; 32 Young, McKinney, Ross, Wahle, Boyle (bb0645) 2007; 76 Ng, Berk, Dean, Bush (bb0390) 2008; 11 Wood (bb0615) 2014; 39 He, Yu, Giegling, Xie, Hartmann, Prehn, Adamski, Kahn, Li, Illig, Wang-Sattler, Rujescu (bb0190) 2012; 2 Labad, Stojanovic-Perez, Montalvo, Sole, Cabezas, Ortega, Moreno, Vilella, Martorell, Reynolds, Gutierrez-Zotes (bb0280) 2015; 60 Sedvall, Wode-Helgodt (bb0535) 1980; 37 Horrobin, Glen, Vaddadi (bb0210) 1994; 13 Oresic, Seppanen-Laakso, Sun, Tang, Therman, Viehman, Mustonen, van Erp, Hyotylainen, Thompson, Toga, Huttunen, Suvisaari, Kaprio, Lonnqvist, Cannon (bb0420) 2012; 4 Yao, Condray, Doughery, Keshavan, Montrose, Matson, McEvoy, Kuddarah-Daouk, Reddy (bb2000) 2012; 7 Ryazantseva, Novitskii, Kublinskaya (bb0490) 2002; 133 Weickert, Weickert, Pillai, Buckley (bb0610) 2013; 35 Lautin, Cordasco, Segarnick, Wood, Mason, Wolkin, Rotrosen (bb0295) 1982; 31 Al Awam, HauSsleiter, Dudley, Donev, Brune, Juckel, Thome (bb0005) 2015; 122 Mondelli, Ciufolini, Murri, Bonaccorso, Di Forti, Giordano, Marques, Zunszain, Morgan, Murray, Pariante, Dazzan (bb0365) 2015; 41 Stojanovic, Martorell, Montalvo, Ortega, Monseny, Vilella, Labad (bb0560) 2014; 41 Mathe, Eberhard, Saaf, Wetterberg (bb0330) 1986; 21 Brown (bb0090) 2011; 93 Koike, Bundo, Iwamoto, Suga, Kuwabara, Ohashi, Shinoda, Takano, Iwashiro, Satomura, Nagai, Natsubori, Tada, Yamasue, Kasai (bb0265) 2014; 4 Schwarz, Van Beveren, Ramsey, Leweke, Rothermundt, Bogerts, Steiner, Guest, Bahn (bb0525) 2014; 40 Quinones, Kaddurah-Daouk (bb0475) 2009; 35 Cai, Li, Yan, Sun, Zhang, Yan, Zhang, Jiang, Zhu, Liu, Fang, Xu, Yuan, Zhang, Hu, Yang, Ye (bb0100) 2012; 11 Miura, Shiga, Katsumi, Kanno-Nozaki, Mashiko, Niwa, Yabe (bb0355) 2014; 29 Emiliani, Sedlak, Sawa (bb0140) 2014; 27 Boskovic, Vovk, Plesnicar, Grabnar (bb0075) 2011; 9 Parletta, Niyonsenga, Duff (bb0425) 2016; 11 Prata, Mechelli, Kapur (bb0465) 2014; 45 Amminger, Schafer, Papageorgiou, Klier, Cotton, Harrigan, Mackinnon, McGorry, Berger (bb0025) 2010; 67 Karoum, Karson, Bigelow, Lawson, Wyatt (bb0240) 1987; 44 Peters (bb0445) 1979; 18 Schwarz, Prabakaran, Whitfield, Major, Leweke, Koethe, McKenna, Bahn (bb0515) 2008; 7 Nagana Gowda, Raferty (bb0380) 2013; 1 Messamore, Yao (bb0350) 2016; 23 Wang, Zhai, Liu (bb0600) 2016; 235 Lee, Kim (bb0300) 2008; 104 Alfredsson, Wiesel (bb0010) 1989; 99 Rossignol, Frye (bb0485) 2014; 5 Hayes, Severance, Leek, Gressitt, Rohleder, Coughlin, Leweke, Yolken, Sawa (bb0185) 2014; 40 Salim (bb0500) 2014; 12 Kahn, Davidson, Knott, Stern, Apter, Davis (bb0230) 1993; 50 Kuloglu, Ustundag, Atmaca, Canatan, Tezcan, Cinkilinc (bb0275) 2002; 20 Fryar-Williams, Strobel (bb0150) 2015; 3 Horrobin (bb0195) 1998; 30 Santoro, Gadelha, Ota, Cunha, Asevedo, Noto, Spindola, Pan, Talarico, Mansur, Silva, Brietzke, Cordeiro, Bressan, Belangero (bb0505) 2015; 16 Yao, Dougherty, Reddy, Keshavan, Montrose, Matson, Rozen, Krishnan, McEvoy, Kaddurah-Daouk (bb0635) 2010; 15 Koga, Serritella, Sawa, Sedlak (bb0260) 2016; 176 Khandaker, Pearson, Zammit, Lewis, Jones (bb0250) 2014; 71 Blesa, Trigo-Damas, Quiroga-Varela, Jackson-Lewis (bb0070) 2015; 9 Mahadik, Yao, Lieberman, S.T.S.P.D.O. (bb0320) 2006 Yao, Stanley, Reddy, Keshavan, Pettegrew (bb0630) 2002; 52 Scheepers, Gispen-de Wied, Westenberg, Kahn (bb0510) 2001; 25 Schwarz, Guest, Rahmoune, Harris, Wang, Leweke, Rothermundt, Bogerts, Koethe, Kranaster, Ohrmann, Suslow, McAllister, Spain, Barnes, van Beveren, Baron-Cohen, Steiner, Torrey, Yolken, Bahn (bb0520) 2012; 17 Xuan, Pan, Qiu, Yang, Su, Liu, Chen, Feng, Fang, Jia, Xing, He (bb0620) 2011; 10 Glen, Glen, Horrobin, Vaddadi, Spellman, Morse-Fisher, Ellis, Skinner (bb0170) 1994; 12 Mossaheb, Schloegelhofer, Schaefer, Fusar-Poli, Smesny, McGorry, Berger, Amminger (bb0375) 2012; 18 Bjerkenstedt, Edman, Hagenfeldt, Sedvall, Wiesel (bb0065) 1985; 147 Brouwer, Luykx, van Boxmeer, Bakker, Kahn (bb0085) 2013; 37 Song, Viggiano, Monda, De Luca (bb0555) 2014; 70 Oresic, Tang, Seppanen-Laakso, Mattila, Saarni, Saarni, Lonnqvist, Sysi-Aho, Hyotylainen, Perala, Suvisaari (bb0415) 2011; 3 Wallstrom, Anderson, LaBaer (bb0595) 2013; 22 Braff, Freedman, Schork, Gottesman (bb0080) 2007; 33 Gouvea, Ota, Noto, Santoro, Spindola, Moretti, Carvalho, Xavier, Rios, Sato, Hayashi, Brietzke, Gadelha, Bressan, Cordeiro, Belangero (bb0175) 2016; 6 Kim, Myint, Verkerk, Scharpe, Steinbusch, Leonard (bb0255) 2009; 59 Domino, Mathews, Tait (bb0135) 1979; 6 Pawelczyk, Grancow, Kotlicka-Antczak, Trafalska, Gebski, Szemraj, Zurner, Pawelczyk (bb0430) 2015; 15 Vankammen, Marder, Murphy, Bunney (bb0585) 1978; 135 Kaiya, Horrobin, Manku, Fisher (bb0235) 1991; 30 Valipour, Saneei, Esmaillzadeh (bb0580) 2014; 99 Lai, Scarr, Udawela, Everall, Chen, Dean (bb0285) 2016; 6 Gattaz, Waldmeier, Beckmann (bb0165) 1982; 66 Yasukawa, Miyaoka, Yasuda, Hayashida, Inagaki, Horiguch (bb0640) 2007; 153 Moher, Liberati, Tetzlaff, Altman, Grp (bb0360) 2009; 6 Bicikova, Hill, Ripova, Mohr, Hampl (bb0060) 2013; 133 Gaebel, Zielasek (bb0160) 2015; 69 Hurlemann, Matusch, Kuhn, Berning, Elmenhorst, Winz, Kolsch, Zilles, Wagner, Maier, Bauer (bb0215) 2008; 195 Prell, Green, Kaufmann, Khandelwal, Morrishow, Kirch, Linnoila, Wyatt (bb0470) 1995; 14 O'Gorman, Gibbons, Brennan (bb0410) 2013; 4 Money, Bousman (bb0370) 2013; 3 Shulman, Tibbo (bb0545) 2005; 50 McEvoy, Baillie, Zhu, Buckley, Keshavan, Nasrallah, Dougherty, Yao, Kaddurah-Daouk (bb0335) 2013; 8 Ramos-Loyo, Medina-Hernandez, Estarron-Espinosa, Canales-Aguirre, Gomez-Pinedo, Cerdan-Sanchez (bb0480) 2013; 44 American Psychiatric Association (bb0015) 2013 Amminger, McGorry (bb0020) 2012; 37 Zumarraga, Davila, Basterreche, Arrue, Goienetxea, Zamalloa, Erkoreka, Bustamante, Inchausti, Gonzalez-Torres, Guimon (bb0655) 2010; 56 Chiappelli, Pocivavsek, Nugent, Notarangelo, Kochunov, Rowland, Schwarcz, Hong (bb0125) 2014; 71 Buchsbaum, Buchsbaum, Hazlett, Haznedar, Newmark, Tang, Hof (bb0095) 2007; 164 Yang, Chen, Sun, Zhao, Qi, Zhou, Cao, Wang, Qiu, Su, Zhao, Wang, Yang, Wu, Feng, He, Jia, Wan (bb0625) 2013; 18 Chaumette, Kebir, Mam-Lam-Fook, Morvan, Bourgin, Godsil, Plaze, Gaillard, Jay, Krebs (bb0115) 2016; 63 Zhang, Sun, Wang, Han, Wang (bb0650) 2012; 137 Cheniaux, Landeira-Fernandez, Versiani (bb0120) 2009; 42 Terlecky, Terlecky, Giordano (bb0570) 2012; 3 Cannon, Yu, Addington, Bearden, Cadenhead, Cornblatt, Heinssen, Jeffries, Mathalon, McGlashan, Perkins, Seidman, Tsuang, Walker, Woods, Kattan (bb0105) 2016; 173 Post, Fink, Carpenter, Goodwin (bb0460) 1975; 32 Khan, Evans, Gunna, Scheffer, Parikh, Mahadik (bb0245) 2002; 58 Krause, Weidinger, Dippel, Riedel, Schwarz, Muller, Myint (bb0270) 2013; 25 Beards, Gayer-Anderson, Borges, Dewey, Fisher, Morgan (bb0050) 2013; 39 Sethi, Brietzke (bb0540) 2015; 19 Kuloglu (10.1016/j.schres.2017.09.021_bb0275) 2002; 20 Mahadik (10.1016/j.schres.2017.09.021_bb0320) 2006 Sabherwal (10.1016/j.schres.2017.09.021_bb0495) 2016; 13 Horrobin (10.1016/j.schres.2017.09.021_bb0210) 1994; 13 Yasukawa (10.1016/j.schres.2017.09.021_bb0640) 2007; 153 American Psychiatric Association (10.1016/j.schres.2017.09.021_bb0015) 2013 Berger (10.1016/j.schres.2017.09.021_bb0055) 1980; 137 Prata (10.1016/j.schres.2017.09.021_bb0465) 2014; 45 Boskovic (10.1016/j.schres.2017.09.021_bb0075) 2011; 9 Prell (10.1016/j.schres.2017.09.021_bb0470) 1995; 14 Braff (10.1016/j.schres.2017.09.021_bb0080) 2007; 33 Hayes (10.1016/j.schres.2017.09.021_bb0185) 2014; 40 Labad (10.1016/j.schres.2017.09.021_bb0280) 2015; 60 Miura (10.1016/j.schres.2017.09.021_bb0355) 2014; 29 Solberg (10.1016/j.schres.2017.09.021_bb0550) 2015; 132 Blesa (10.1016/j.schres.2017.09.021_bb0070) 2015; 9 Buchsbaum (10.1016/j.schres.2017.09.021_bb0095) 2007; 164 Obi (10.1016/j.schres.2017.09.021_bb0405) 1979; 43 Peters (10.1016/j.schres.2017.09.021_bb0445) 1979; 18 Santoro (10.1016/j.schres.2017.09.021_bb0505) 2015; 16 Horrobin (10.1016/j.schres.2017.09.021_bb0205) 1989; 25 Koga (10.1016/j.schres.2017.09.021_bb0260) 2016; 176 Beards (10.1016/j.schres.2017.09.021_bb0050) 2013; 39 Kahn (10.1016/j.schres.2017.09.021_bb0230) 1993; 50 Khandaker (10.1016/j.schres.2017.09.021_bb0250) 2014; 71 Schwarz (10.1016/j.schres.2017.09.021_bb0525) 2014; 40 Horrobin (10.1016/j.schres.2017.09.021_bb0200) 1999 Scheepers (10.1016/j.schres.2017.09.021_bb0510) 2001; 25 Cotter (10.1016/j.schres.2017.09.021_bb0130) 2002; 181 Yao (10.1016/j.schres.2017.09.021_bb2000) 2012; 7 Kaiya (10.1016/j.schres.2017.09.021_bb0235) 1991; 30 Scottish Schizophrenia Research Group (10.1016/j.schres.2017.09.021_bb0530) 2000; 176 Al Awam (10.1016/j.schres.2017.09.021_bb0005) 2015; 122 Arvindakshan (10.1016/j.schres.2017.09.021_bb0035) 2003; 53 Mahadik (10.1016/j.schres.2017.09.021_bb0315) 1998; 43 Song (10.1016/j.schres.2017.09.021_bb0555) 2014; 70 Quinones (10.1016/j.schres.2017.09.021_bb0475) 2009; 35 Khan (10.1016/j.schres.2017.09.021_bb0245) 2002; 58 Fryar-Williams (10.1016/j.schres.2017.09.021_bb0150) 2015; 3 Pickar (10.1016/j.schres.2017.09.021_bb0450) 1990; 47 Wood (10.1016/j.schres.2017.09.021_bb0615) 2014; 39 Liu (10.1016/j.schres.2017.09.021_bb0310) 2015; 13 Nilsson-Todd (10.1016/j.schres.2017.09.021_bb0395) 2007; 19 Schwarz (10.1016/j.schres.2017.09.021_bb0515) 2008; 7 Cheniaux (10.1016/j.schres.2017.09.021_bb0120) 2009; 42 Zhang (10.1016/j.schres.2017.09.021_bb0650) 2012; 137 Bicikova (10.1016/j.schres.2017.09.021_bb0060) 2013; 133 Vankammen (10.1016/j.schres.2017.09.021_bb0585) 1978; 135 Xuan (10.1016/j.schres.2017.09.021_bb0620) 2011; 10 Anand (10.1016/j.schres.2017.09.021_bb0030) 2002; 44 He (10.1016/j.schres.2017.09.021_bb0190) 2012; 2 Salim (10.1016/j.schres.2017.09.021_bb0500) 2014; 12 Mossaheb (10.1016/j.schres.2017.09.021_bb0375) 2012; 18 Chan (10.1016/j.schres.2017.09.021_bb0110) 2015; 33 Nyback (10.1016/j.schres.2017.09.021_bb0400) 1983; 9 Sethi (10.1016/j.schres.2017.09.021_bb0540) 2015; 19 Post (10.1016/j.schres.2017.09.021_bb0460) 1975; 32 Karoum (10.1016/j.schres.2017.09.021_bb0240) 1987; 44 Schwarz (10.1016/j.schres.2017.09.021_bb0520) 2012; 17 Stojanovic (10.1016/j.schres.2017.09.021_bb0560) 2014; 41 Pawelczyk (10.1016/j.schres.2017.09.021_bb0430) 2015; 15 Bjerkenstedt (10.1016/j.schres.2017.09.021_bb0065) 1985; 147 Focking (10.1016/j.schres.2017.09.021_bb0145) 2016; 16 Larsen (10.1016/j.schres.2017.09.021_bb0290) 2011; 41 Brown (10.1016/j.schres.2017.09.021_bb0090) 2011; 93 Gaebel (10.1016/j.schres.2017.09.021_bb0160) 2015; 69 Emiliani (10.1016/j.schres.2017.09.021_bb0140) 2014; 27 Zumarraga (10.1016/j.schres.2017.09.021_bb0655) 2010; 56 Cannon (10.1016/j.schres.2017.09.021_bb0105) 2016; 173 Guest (10.1016/j.schres.2017.09.021_bb0180) 2016; 10 Nakano (10.1016/j.schres.2017.09.021_bb0385) 2010; 25 Chaumette (10.1016/j.schres.2017.09.021_bb0115) 2016; 63 Sedvall (10.1016/j.schres.2017.09.021_bb0535) 1980; 37 Yao (10.1016/j.schres.2017.09.021_bb0630) 2002; 52 Chiappelli (10.1016/j.schres.2017.09.021_bb0125) 2014; 71 McNamara (10.1016/j.schres.2017.09.021_bb0345) 2016; 10 Waziri (10.1016/j.schres.2017.09.021_bb0605) 1983; 143 Yao (10.1016/j.schres.2017.09.021_bb0635) 2010; 15 Parletta (10.1016/j.schres.2017.09.021_bb0425) 2016; 11 Krause (10.1016/j.schres.2017.09.021_bb0270) 2013; 25 Mondelli (10.1016/j.schres.2017.09.021_bb0365) 2015; 41 Rossignol (10.1016/j.schres.2017.09.021_bb0485) 2014; 5 Valipour (10.1016/j.schres.2017.09.021_bb0580) 2014; 99 Terlecky (10.1016/j.schres.2017.09.021_bb0570) 2012; 3 Lai (10.1016/j.schres.2017.09.021_bb0285) 2016; 6 Kim (10.1016/j.schres.2017.09.021_bb0255) 2009; 59 Wang (10.1016/j.schres.2017.09.021_bb0600) 2016; 235 McEvoy (10.1016/j.schres.2017.09.021_bb0335) 2013; 8 Pickard (10.1016/j.schres.2017.09.021_bb0455) 2015; 29 Glen (10.1016/j.schres.2017.09.021_bb0170) 1994; 12 Lee (10.1016/j.schres.2017.09.021_bb0300) 2008; 104 Brouwer (10.1016/j.schres.2017.09.021_bb0085) 2013; 37 Ng (10.1016/j.schres.2017.09.021_bb0390) 2008; 11 Gattaz (10.1016/j.schres.2017.09.021_bb0165) 1982; 66 Young (10.1016/j.schres.2017.09.021_bb0645) 2007; 76 Amminger (10.1016/j.schres.2017.09.021_bb0020) 2012; 37 Moher (10.1016/j.schres.2017.09.021_bb0360) 2009; 6 Cai (10.1016/j.schres.2017.09.021_bb0100) 2012; 11 Amminger (10.1016/j.schres.2017.09.021_bb0025) 2010; 67 Tsang (10.1016/j.schres.2017.09.021_bb0575) 2006; 5 Wallstrom (10.1016/j.schres.2017.09.021_bb0595) 2013; 22 Markianos (10.1016/j.schres.2017.09.021_bb0325) 1992; 32 Horrobin (10.1016/j.schres.2017.09.021_bb0195) 1998; 30 Koike (10.1016/j.schres.2017.09.021_bb0265) 2014; 4 Ballesteros (10.1016/j.schres.2017.09.021_bb0040) 2013; 124 Gouvea (10.1016/j.schres.2017.09.021_bb0175) 2016; 6 Bates (10.1016/j.schres.2017.09.021_bb0045) 1991; 6 Ramos-Loyo (10.1016/j.schres.2017.09.021_bb0480) 2013; 44 Fukushima (10.1016/j.schres.2017.09.021_bb0155) 2014; 9 Shulman (10.1016/j.schres.2017.09.021_bb0545) 2005; 50 Oresic (10.1016/j.schres.2017.09.021_bb0420) 2012; 4 Lautin (10.1016/j.schres.2017.09.021_bb0295) 1982; 31 Mathe (10.1016/j.schres.2017.09.021_bb0330) 1986; 21 Kaddurah-Daouk (10.1016/j.schres.2017.09.021_bb0225) 2007; 12 Oresic (10.1016/j.schres.2017.09.021_bb0415) 2011; 3 Perkins (10.1016/j.schres.2017.09.021_bb0440) 2005; 162 Taneli (10.1016/j.schres.2017.09.021_bb0565) 2004; 35 Nagana Gowda (10.1016/j.schres.2017.09.021_bb0380) 2013; 1 O'Gorman (10.1016/j.schres.2017.09.021_bb0410) 2013; 4 McNamara (10.1016/j.schres.2017.09.021_bb0340) 2016; 18 Money (10.1016/j.schres.2017.09.021_bb0370) 2013; 3 Ryazantseva (10.1016/j.schres.2017.09.021_bb0490) 2002; 133 Messamore (10.1016/j.schres.2017.09.021_bb0350) 2016; 23 Peng (10.1016/j.schres.2017.09.021_bb0435) 2015; 6 Yang (10.1016/j.schres.2017.09.021_bb0625) 2013; 18 Domino (10.1016/j.schres.2017.09.021_bb0135) 1979; 6 Liu (10.1016/j.schres.2017.09.021_bb0305) 2014; 10 Walker (10.1016/j.schres.2017.09.021_bb0590) 2002; 15 Weickert (10.1016/j.schres.2017.09.021_bb0610) 2013; 35 Jacobsen (10.1016/j.schres.2017.09.021_bb0220) 1997; 154 Alfredsson (10.1016/j.schres.2017.09.021_bb0010) 1989; 99 Hurlemann (10.1016/j.schres.2017.09.021_bb0215) 2008; 195 |
| References_xml | – volume: 10 start-page: 431 year: 2016 end-page: 443 ident: bb0180 article-title: The emergence of point-of-care blood-based biomarker testing for psychiatric disorders: enabling personalized medicine publication-title: Biomark. Med – volume: 29 start-page: 199 year: 2014 end-page: 202 ident: bb0355 article-title: Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia publication-title: Hum. Psychopharmacol. – volume: 7 start-page: 4266 year: 2008 end-page: 4277 ident: bb0515 article-title: High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides publication-title: J. Proteome Res. – volume: 33 start-page: 21 year: 2007 end-page: 32 ident: bb0080 article-title: Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder publication-title: Schizophr. Bull. – volume: 25 start-page: 562 year: 1989 end-page: 568 ident: bb0205 article-title: Essential fatty acids in plasma phospholipids in schizophrenics publication-title: Biol. Psychiatry – volume: 176 start-page: 52 year: 2016 end-page: 71 ident: bb0260 article-title: Implications for reactive species in schizophrenia pathogenesis publication-title: Schizophr. Res. – volume: 8 year: 2013 ident: bb0335 article-title: Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics publication-title: PLoS One – volume: 35 start-page: 401 year: 2004 end-page: 405 ident: bb0565 article-title: Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia publication-title: Arch. Med. Res. – volume: 10 start-page: 203 year: 2016 end-page: 211 ident: bb0345 article-title: Adolescents with or at ultra-high risk for bipolar disorder exhibit erythrocyte docosahexaenoic acid and eicosapentaenoic acid deficits: a candidate prodromal risk biomarker publication-title: Early Interv. Psychiatry – volume: 76 start-page: 73 year: 2007 end-page: 85 ident: bb0645 article-title: Biomarkers of oxidative stress in schizophrenic and control subjects publication-title: Prostaglandins Leukot. Essent. Fat. Acids – volume: 14 start-page: 93 year: 1995 end-page: 104 ident: bb0470 article-title: Histamine metabolites in cerebrospinal-fluid of patients with chronic-schizophrenia - their relationships to levels of other aminergic transmitters and ratings of symptoms publication-title: Schizophr. Res. – volume: 4 year: 2014 ident: bb0265 article-title: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study publication-title: Transl. Psychiatry – volume: 1 start-page: 227 year: 2013 end-page: 240 ident: bb0380 article-title: Biomarker discovery and translation in metabolomics publication-title: Curr. Metabolomics – volume: 147 start-page: 276 year: 1985 end-page: 282 ident: bb0065 article-title: Plasma amino-acids in relation to cerebrospinal-fluid monoamine metabolites in schizophrenic-patients and healthy controls publication-title: Brit. J. Psychiatry – volume: 133 start-page: 77 year: 2013 end-page: 83 ident: bb0060 article-title: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia publication-title: J. Steroid Biochem. Mol. Biol. – volume: 35 start-page: 165 year: 2009 end-page: 176 ident: bb0475 article-title: Metabolomics tools for identifying biomarkers for neuropsychiatric diseases publication-title: Neurobiol. Dis. – volume: 6 start-page: 1 year: 1991 end-page: 7 ident: bb0045 article-title: Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant with schizophrenia publication-title: Schizophr. Res. – volume: 37 start-page: 1587 year: 2013 end-page: 1596 ident: bb0085 article-title: NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: a meta-analysis of case control studies publication-title: Neurosci. Biobehav. Rev. – volume: 32 start-page: 288 year: 1992 end-page: 292 ident: bb0325 article-title: Biogenic-amine metabolites in plasma of drug-naive schizophrenic-patients - associations with symptomatology publication-title: Biol. Psychiatry – volume: 31 start-page: 3051 year: 1982 end-page: 3056 ident: bb0295 article-title: Red-cell phospholipids in schizophrenia publication-title: Life Sci. – volume: 9 start-page: 301 year: 1983 end-page: 308 ident: bb0400 article-title: Cerebroventricular size and cerebrospinal-fluid monoamine metabolites in schizophrenic-patients and healthy-volunteers publication-title: Psychiatry Res. – volume: 9 start-page: 301 year: 2011 end-page: 312 ident: bb0075 article-title: Oxidative stress in schizophrenia publication-title: Curr. Neuropharmacol. – volume: 13 start-page: 226 year: 2015 ident: bb0310 article-title: Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study publication-title: J. Transl. Med. – volume: 39 start-page: 24 year: 2014 end-page: 33 ident: bb0615 article-title: Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology publication-title: Neuropsychopharmacology – volume: 13 start-page: 1141 year: 2016 end-page: 1155 ident: bb0495 article-title: Blood biomarker discovery in drug-free schizophrenia: the contribution of proteomics and multiplex immunoassays publication-title: Expert Rev. Proteomics – volume: 58 start-page: 1 year: 2002 end-page: 10 ident: bb0245 article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics publication-title: Schizophr. Res. – volume: 6 start-page: 628 year: 2015 end-page: 637 ident: bb0435 article-title: Functional metabolomics: from biomarker discovery to metabolome reprogramming publication-title: Protein Cell – volume: 143 start-page: 69 year: 1983 end-page: 73 ident: bb0605 article-title: Plasma serine to cysteine ratio as a biological marker for psychosis publication-title: Brit. J. Psychiatry – volume: 18 start-page: 300 year: 2016 end-page: 306 ident: bb0340 article-title: Meta-analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder publication-title: Bipolar Disord. – volume: 63 start-page: 262 year: 2016 end-page: 270 ident: bb0115 article-title: Salivary cortisol in early psychosis: new findings and meta-analysis publication-title: Psychoneuroendocrinology – volume: 44 start-page: 604 year: 1987 end-page: 607 ident: bb0240 article-title: Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. [Erratum appears in Arch Gen Psychiatry 1987 Oct; 44 (1):861] publication-title: Arch. Gen. Psychiatry – volume: 133 start-page: 84 year: 2002 end-page: 86 ident: bb0490 article-title: Changes in the lipid phase of erythrocyte membranes in patients with paranoid schizophrenia publication-title: Bull. Exp. Biol. Med. – volume: 21 start-page: 1024 year: 1986 end-page: 1030 ident: bb0330 article-title: Plasma prostaglandin E2 metabolite—measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2—in twins with schizophrenic disorder publication-title: Biol. Psychiatry – volume: 11 start-page: 851 year: 2008 end-page: 876 ident: bb0390 article-title: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications publication-title: IJNP – volume: 33 start-page: 712 year: 2015 end-page: 723 ident: bb0110 article-title: Commercialisation of biomarker tests for mental illnesses: advances one obstacles publication-title: Trends Biotechnol. – volume: 12 start-page: 934 year: 2007 end-page: 945 ident: bb0225 article-title: Metabolomic mapping of atypical antipsychotic effects in schizophrenia publication-title: Mol. Psychiatry – volume: 15 start-page: 1 year: 2015 end-page: 13 ident: bb0430 article-title: Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods publication-title: BMC Psychiatry – volume: 43 start-page: 447 year: 1979 end-page: 454 ident: bb0405 article-title: Fatty acid profiles in mental disease: part 1. Linoleate variations in schizophrenia publication-title: J. Neurol. Sci. – volume: 66 start-page: 350 year: 1982 end-page: 360 ident: bb0165 article-title: CSF monoamine metabolites in schizophrenic-patients publication-title: Acta Psychiatr. Scand. – volume: 17 start-page: 494 year: 2012 end-page: 502 ident: bb0520 article-title: Identification of a biological signature for schizophrenia in serum publication-title: Mol. Psychiatry – volume: 6 year: 2009 ident: bb0360 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med. – volume: 50 start-page: 695 year: 2005 end-page: 702 ident: bb0545 article-title: Neuroactive steroids in schizophrenia publication-title: Can. J. Psychiatr. – volume: 99 start-page: 3863 year: 2014 end-page: 3872 ident: bb0580 article-title: Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies publication-title: J. Clin. Endocrinol. Metab. – volume: 35 start-page: 3 year: 2013 end-page: 9 ident: bb0610 article-title: Biomarkers in schizophrenia: a brief conceptual consideration publication-title: Dis. Markers – year: 2006 ident: bb0320 article-title: Phospholipids in schizophrenia publication-title: Textbook of Schizophrenia – volume: 153 start-page: 203 year: 2007 end-page: 207 ident: bb0640 article-title: Increased urinary excretion of biopyrrins, oxidative metabolites of bilirubin, in patients with schizophrenia publication-title: Psychiatry Res. – volume: 16 start-page: 441 year: 2015 end-page: 446 ident: bb0505 article-title: Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls publication-title: World J. Biol. Psychiatry – volume: 3 start-page: 117 year: 2013 ident: bb0370 article-title: Metabolomics of psychotic disorders publication-title: Metabolomics – volume: 16 year: 2016 ident: bb0145 article-title: Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? publication-title: BMC Psychiatry – volume: 40 start-page: 963 year: 2014 end-page: 972 ident: bb0185 article-title: Inflammatory molecular signature associated with infectious agents in psychosis publication-title: Schizophr. Bull. – volume: 137 start-page: 174 year: 1980 end-page: 180 ident: bb0055 article-title: CSF monoamine metabolites in depression and schizophrenia publication-title: Am. J. Psychiatry – volume: 41 start-page: 1162 year: 2015 end-page: 1170 ident: bb0365 article-title: Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis publication-title: Schizophr. Bull. – volume: 6 start-page: 102 year: 2016 end-page: 117 ident: bb0285 article-title: Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics publication-title: World J. Psychiatry – volume: 60 start-page: 163 year: 2015 end-page: 169 ident: bb0280 article-title: Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin publication-title: J. Psychiatr. Res. – volume: 27 start-page: 185 year: 2014 end-page: 190 ident: bb0140 article-title: Oxidative stress and schizophrenia: recent breakthroughs from an old story publication-title: Curr. Opin. Psychiatry – volume: 23 start-page: D112 year: 2016 ident: bb0350 article-title: Phospholipid, arachidonate and eicosanoid signaling in schizophrenia publication-title: OCL – volume: 71 start-page: 1121 year: 2014 end-page: 1128 ident: bb0250 article-title: Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study publication-title: JAMA Psychiatry – volume: 67 start-page: 146 year: 2010 end-page: 154 ident: bb0025 article-title: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders a randomized, placebo-controlled trial publication-title: Arch. Gen. Psychiatry – volume: 71 start-page: 761 year: 2014 end-page: 768 ident: bb0125 article-title: Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance publication-title: JAMA Psychiatry – volume: 41 start-page: 23 year: 2014 end-page: 32 ident: bb0560 article-title: Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms publication-title: Psychoneuroendocrinology – volume: 10 start-page: 5433 year: 2011 end-page: 5443 ident: bb0620 article-title: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action publication-title: J. Proteome Res. – volume: 53 start-page: 56 year: 2003 end-page: 64 ident: bb0035 article-title: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients publication-title: Biol. Psychiatry – volume: 11 start-page: 4338 year: 2012 end-page: 4350 ident: bb0100 article-title: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone publication-title: J. Proteome Res. – volume: 11 year: 2016 ident: bb0425 article-title: Omega-3 and Omega-6 polyunsaturated fatty acid levels and correlations with symptoms in children with attention deficit hyperactivity disorder, autistic Spectrum disorder and typically developing controls publication-title: PLoS One – volume: 30 start-page: 193 year: 1998 end-page: 208 ident: bb0195 article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia publication-title: Schizophr. Res. – volume: 124 start-page: 2209 year: 2013 end-page: 2215 ident: bb0040 article-title: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia publication-title: Clin. Neurophysiol. – volume: 104 start-page: 36 year: 2008 end-page: 43 ident: bb0300 article-title: Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls publication-title: Schizophr. Res. – volume: 30 start-page: 357 year: 1991 end-page: 362 ident: bb0235 article-title: Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan publication-title: Biol. Psychiatry – volume: 42 start-page: 293 year: 2009 end-page: 298 ident: bb0120 article-title: The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10 publication-title: Psychopathology – volume: 9 year: 2014 ident: bb0155 article-title: Quantitative analyses of schizophrenia-associated metabolites in serum: serum publication-title: PLoS One – volume: 12 start-page: 53 year: 1994 end-page: 61 ident: bb0170 article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases publication-title: Schizophr. Res. – volume: 56 start-page: 774 year: 2010 end-page: 779 ident: bb0655 article-title: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients publication-title: Neurochem. Int. – volume: 25 start-page: 468 year: 2001 end-page: 475 ident: bb0510 article-title: The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients publication-title: Neuropsychopharmacology – volume: 13 start-page: 195 year: 1994 end-page: 207 ident: bb0210 article-title: The membrane hypothesis of schizophrenia publication-title: Schizophr. Res. – volume: 162 start-page: 1785 year: 2005 end-page: 1804 ident: bb0440 article-title: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis publication-title: Am. J. Psychiatry – volume: 235 start-page: 83 year: 2016 end-page: 89 ident: bb0600 article-title: Serum folate levels in schizophrenia: a meta-analysis publication-title: Psychiatry Res. – volume: 3 start-page: 93 year: 2012 end-page: 97 ident: bb0570 article-title: Peroxisomes, oxidative stress and inflammation publication-title: World J. Biol. Psychiatry – volume: 9 start-page: 91 year: 2015 ident: bb0070 article-title: Oxidative stress and Parkinson's disease publication-title: Front. Neuroanat. – volume: 99 start-page: 322 year: 1989 end-page: 327 ident: bb0010 article-title: Monoamine metabolites and amino-acids in serum from schizophrenic-patients before and during sulpiride treatment publication-title: Psychopharmacology – volume: 69 start-page: 661 year: 2015 end-page: 673 ident: bb0160 article-title: Schizophrenia in 2020: trends in diagnosis and therapy publication-title: Psychiatry Clin. Neurosci. – volume: 37 start-page: 309 year: 2012 end-page: 310 ident: bb0020 article-title: Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders publication-title: Neuropsychopharmacology – volume: 6 start-page: e908 year: 2016 ident: bb0175 article-title: Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis publication-title: Transl. Psychiatry – volume: 93 start-page: 23 year: 2011 end-page: 58 ident: bb0090 article-title: The environment and susceptibility to schizophrenia publication-title: Prog. Neurobiol. – volume: 2 year: 2012 ident: bb0190 article-title: Schizophrenia shows a unique metabolomics signature in plasma publication-title: Transl. Psychiatry – volume: 181 start-page: 363 year: 2002 end-page: 365 ident: bb0130 article-title: Stress and the progression of the developmental hypothesis of schizophrenia publication-title: Brit. J. Psychiatry – volume: 122 start-page: S111 year: 2015 end-page: 122 ident: bb0005 article-title: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia publication-title: J. Neural Transm. – volume: 3 start-page: 19 year: 2011 ident: bb0415 article-title: Metabolome in schizophrenia and other psychotic disorders: a general population-based study publication-title: Genome Med. – volume: 15 start-page: 938 year: 2010 end-page: 953 ident: bb0635 article-title: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia publication-title: Mol. Psychiatry – volume: 164 start-page: 1072 year: 2007 end-page: 1081 ident: bb0095 article-title: Relative glucose metabolic rate higher in white matter in patients with schizophrenia publication-title: Am. J. Psychiatry – volume: 154 start-page: 69 year: 1997 end-page: 74 ident: bb0220 article-title: Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia publication-title: Am. J. Psychiatry – volume: 6 start-page: 331 year: 1979 end-page: 334 ident: bb0135 article-title: Urinary neurotransmitter metabolites in drug-free chronic-schizophrenic patients measured by gas-chromatography selected positive-ion monitoring publication-title: Biomed. Mass Spectrom. – volume: 5 start-page: 756 year: 2006 end-page: 760 ident: bb0575 article-title: Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients publication-title: J. Proteome Res. – year: 2013 ident: bb0015 article-title: Diagnostic and Statistical Manual of Mental Disorders – volume: 18 start-page: 576 year: 2012 end-page: 591 ident: bb0375 article-title: Polyunsaturated fatty acids in emerging psychosis publication-title: Curr. Pharm. Des. – volume: 59 start-page: 123 year: 2009 end-page: 129 ident: bb0255 article-title: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients publication-title: Neuropsychobiology – volume: 4 start-page: 1 year: 2012 end-page: 10 ident: bb0420 article-title: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia publication-title: Genome Med. – volume: 41 start-page: 1461 year: 2011 end-page: 1469 ident: bb0290 article-title: Early detection of psychosis: positive effects on 5-year outcome publication-title: Psychol. Med. – volume: 3 year: 2015 ident: bb0150 article-title: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis publication-title: Biomark. Res. – volume: 18 start-page: 15 year: 1979 end-page: 18 ident: bb0445 article-title: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology publication-title: Eur. Neurol. – volume: 32 start-page: 1063 year: 1975 end-page: 1069 ident: bb0460 article-title: Cerebrospinal fluid amine metabolites in acute schizophrenia publication-title: Arch. Gen. Psychiatry – year: 1999 ident: bb0200 article-title: The Membrane Phospholipid Concept of Schizophrenia – volume: 70 start-page: 133 year: 2014 end-page: 141 ident: bb0555 article-title: Peripheral glutamate levels in schizophrenia: evidence from a meta-analysis publication-title: Neuropsychobiology – volume: 132 start-page: 293 year: 2015 end-page: 300 ident: bb0550 article-title: Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia publication-title: Acta Psychiatr. Scand. – volume: 4 year: 2013 ident: bb0410 article-title: Metabolomics in the identification of biomarkers of dietary intake publication-title: CSBJ – volume: 22 start-page: 747 year: 2013 end-page: 755 ident: bb0595 article-title: Biomarker discovery for heterogeneous diseases publication-title: Cancer Epidemiol. Biomark. Prev. – volume: 12 start-page: 140 year: 2014 end-page: 147 ident: bb0500 article-title: Oxidative stress and psychological disorders publication-title: Curr. Neuropharmacol. – volume: 176 start-page: 290 year: 2000 end-page: 293 ident: bb0530 article-title: Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia publication-title: Brit. J. Psychiatry – volume: 137 start-page: 293 year: 2012 end-page: 300 ident: bb0650 article-title: Modern analytical techniques in metabolomics analysis publication-title: Analyst – volume: 25 start-page: 139 year: 2010 end-page: 144 ident: bb0385 article-title: Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study publication-title: Hum. Psychopharmacol. Clin. Exp. – volume: 44 start-page: 212 year: 2002 end-page: 219 ident: bb0030 article-title: CSF amines and their metabolites in first episode drug naive schizophrenic patients and their correlations with dimensions of schizophrenia publication-title: Indian J. Psychiatry – volume: 19 year: 2015 ident: bb0540 article-title: Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders publication-title: Int. J. Neuropsychopharmacol. – volume: 20 start-page: 171 year: 2002 end-page: 175 ident: bb0275 article-title: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder publication-title: Cell Biochem. Funct. – volume: 135 start-page: 567 year: 1978 end-page: 569 ident: bb0585 article-title: MAO activity, CSF amine metabolites, and drug-free improvement in schizophrenia publication-title: Am. J. Psychiatry – volume: 195 start-page: 579 year: 2008 end-page: 590 ident: bb0215 article-title: 5-HT2A receptor density is decreased in the at-risk mental state publication-title: Psychopharmacology – volume: 52 start-page: 823 year: 2002 end-page: 830 ident: bb0630 article-title: Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites publication-title: Biol. Psychiatry – volume: 15 start-page: 10 year: 2002 end-page: 17 ident: bb0590 article-title: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis publication-title: Neuropsychiatry Neuropsychol. Behav. Neurol. – volume: 29 start-page: 138 year: 2015 end-page: 143 ident: bb0455 article-title: Schizophrenia biomarkers: translating the descriptive into the diagnostic publication-title: J. Psychopharmacol. – volume: 19 start-page: 45 year: 2007 end-page: 52 ident: bb0395 article-title: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites publication-title: Acta Neuropsychiatr. – volume: 45 start-page: 134 year: 2014 end-page: 141 ident: bb0465 article-title: Clinically meaningful biomarkers for psychosis: a systematic and quantitative review publication-title: Neurosci. Biobehav. Rev. – volume: 7 start-page: e42165 year: 2012 ident: bb2000 article-title: Associations between purine metabolites and clinical symptoms in schizophrenia publication-title: PLoS One – volume: 25 start-page: 389 year: 2013 end-page: 397 ident: bb0270 article-title: Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia publication-title: Psychiatr. Danub. – volume: 37 start-page: 1113 year: 1980 end-page: 1116 ident: bb0535 article-title: Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients publication-title: Arch. Gen. Psychiatry – volume: 50 start-page: 599 year: 1993 end-page: 605 ident: bb0230 article-title: Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment publication-title: Arch. Gen. Psychiatry – volume: 10 start-page: 2398 year: 2014 end-page: 2406 ident: bb0305 article-title: GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells publication-title: Mol. BioSyst. – volume: 18 start-page: 67 year: 2013 end-page: 78 ident: bb0625 article-title: Potential metabolite markers of schizophrenia publication-title: Mol. Psychiatry – volume: 39 start-page: 740 year: 2013 end-page: 747 ident: bb0050 article-title: Life events and psychosis: a review and meta-analysis publication-title: Schizophr. Bull. – volume: 40 start-page: 787 year: 2014 end-page: 795 ident: bb0525 article-title: Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways publication-title: Schizophr. Bull. – volume: 47 start-page: 641 year: 1990 end-page: 648 ident: bb0450 article-title: Cerebrospinal-fluid and plasma monoamine metabolites and their relation to psychosis - implications for regional brain-dysfunction in schizophrenia publication-title: Arch. Gen. Psychiatry – volume: 44 start-page: 154 year: 2013 end-page: 161 ident: bb0480 article-title: Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry – volume: 43 start-page: 674 year: 1998 end-page: 679 ident: bb0315 article-title: Elevated plasma lipid peroxides at the onset of nonaffective psychosis publication-title: Biol. Psychiatry – volume: 173 start-page: 980 year: 2016 end-page: 988 ident: bb0105 article-title: An individualized risk calculator for research in prodromal psychosis publication-title: Am. J. Psychiatry – volume: 5 start-page: 150 year: 2014 ident: bb0485 article-title: Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism publication-title: Front. Physiol. – volume: 39 start-page: 740 issue: 4 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0050 article-title: Life events and psychosis: a review and meta-analysis publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbt065 – volume: 15 start-page: 938 issue: 9 year: 2010 ident: 10.1016/j.schres.2017.09.021_bb0635 article-title: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia publication-title: Mol. Psychiatry doi: 10.1038/mp.2009.33 – volume: 9 issue: 7 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0155 article-title: Quantitative analyses of schizophrenia-associated metabolites in serum: serum d-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients publication-title: PLoS One doi: 10.1371/journal.pone.0101652 – volume: 99 start-page: 3863 issue: 10 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0580 article-title: Serum vitamin D levels in relation to schizophrenia: a systematic review and meta-analysis of observational studies publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2014-1887 – volume: 76 start-page: 73 issue: 2 year: 2007 ident: 10.1016/j.schres.2017.09.021_bb0645 article-title: Biomarkers of oxidative stress in schizophrenic and control subjects publication-title: Prostaglandins Leukot. Essent. Fat. Acids doi: 10.1016/j.plefa.2006.11.003 – volume: 12 start-page: 140 issue: 2 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0500 article-title: Oxidative stress and psychological disorders publication-title: Curr. Neuropharmacol. doi: 10.2174/1570159X11666131120230309 – volume: 4 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0265 article-title: A snapshot of plasma metabolites in first-episode schizophrenia: a capillary electrophoresis time-of-flight mass spectrometry study publication-title: Transl. Psychiatry doi: 10.1038/tp.2014.19 – volume: 235 start-page: 83 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0600 article-title: Serum folate levels in schizophrenia: a meta-analysis publication-title: Psychiatry Res. doi: 10.1016/j.psychres.2015.11.045 – volume: 27 start-page: 185 issue: 3 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0140 article-title: Oxidative stress and schizophrenia: recent breakthroughs from an old story publication-title: Curr. Opin. Psychiatry doi: 10.1097/YCO.0000000000000054 – volume: 10 start-page: 203 issue: 3 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0345 article-title: Adolescents with or at ultra-high risk for bipolar disorder exhibit erythrocyte docosahexaenoic acid and eicosapentaenoic acid deficits: a candidate prodromal risk biomarker publication-title: Early Interv. Psychiatry doi: 10.1111/eip.12282 – volume: 22 start-page: 747 issue: 5 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0595 article-title: Biomarker discovery for heterogeneous diseases publication-title: Cancer Epidemiol. Biomark. Prev. doi: 10.1158/1055-9965.EPI-12-1236 – volume: 154 start-page: 69 issue: 1 year: 1997 ident: 10.1016/j.schres.2017.09.021_bb0220 article-title: Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/ajp.154.1.69 – volume: 47 start-page: 641 issue: 7 year: 1990 ident: 10.1016/j.schres.2017.09.021_bb0450 article-title: Cerebrospinal-fluid and plasma monoamine metabolites and their relation to psychosis - implications for regional brain-dysfunction in schizophrenia publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1990.01810190041006 – volume: 41 start-page: 23 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0560 article-title: Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2013.12.005 – volume: 9 start-page: 91 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0070 article-title: Oxidative stress and Parkinson's disease publication-title: Front. Neuroanat. doi: 10.3389/fnana.2015.00091 – volume: 37 start-page: 309 issue: 1 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb0020 article-title: Update on omega-3 polyunsaturated fatty acids in early-stage psychotic disorders publication-title: Neuropsychopharmacology doi: 10.1038/npp.2011.187 – volume: 71 start-page: 761 issue: 7 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0125 article-title: Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2014.243 – volume: 15 start-page: 1 issue: 97 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0430 article-title: Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods publication-title: BMC Psychiatry – volume: 25 start-page: 139 issue: 2 year: 2010 ident: 10.1016/j.schres.2017.09.021_bb0385 article-title: Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study publication-title: Hum. Psychopharmacol. Clin. Exp. doi: 10.1002/hup.1102 – volume: 133 start-page: 84 issue: 1 year: 2002 ident: 10.1016/j.schres.2017.09.021_bb0490 article-title: Changes in the lipid phase of erythrocyte membranes in patients with paranoid schizophrenia publication-title: Bull. Exp. Biol. Med. doi: 10.1023/A:1015172914991 – volume: 35 start-page: 3 issue: 1 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0610 article-title: Biomarkers in schizophrenia: a brief conceptual consideration publication-title: Dis. Markers doi: 10.1155/2013/510402 – volume: 137 start-page: 293 issue: 2 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb0650 article-title: Modern analytical techniques in metabolomics analysis publication-title: Analyst doi: 10.1039/C1AN15605E – volume: 7 start-page: 4266 issue: 10 year: 2008 ident: 10.1016/j.schres.2017.09.021_bb0515 article-title: High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides publication-title: J. Proteome Res. doi: 10.1021/pr800188y – volume: 4 start-page: 1 issue: 1 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb0420 article-title: Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia publication-title: Genome Med. doi: 10.1186/gm300 – volume: 1 start-page: 227 issue: 3 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0380 article-title: Biomarker discovery and translation in metabolomics publication-title: Curr. Metabolomics doi: 10.2174/2213235X113019990005 – volume: 37 start-page: 1113 issue: 10 year: 1980 ident: 10.1016/j.schres.2017.09.021_bb0535 article-title: Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Their relationships in schizophrenic patients publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1980.01780230031004 – volume: 50 start-page: 695 issue: 11 year: 2005 ident: 10.1016/j.schres.2017.09.021_bb0545 article-title: Neuroactive steroids in schizophrenia publication-title: Can. J. Psychiatr. doi: 10.1177/070674370505001109 – volume: 15 start-page: 10 issue: 1 year: 2002 ident: 10.1016/j.schres.2017.09.021_bb0590 article-title: Plasma hormones and catecholamine metabolites in monozygotic twins discordant for psychosis publication-title: Neuropsychiatry Neuropsychol. Behav. Neurol. – volume: 4 issue: 5 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0410 article-title: Metabolomics in the identification of biomarkers of dietary intake publication-title: CSBJ doi: 10.5936/csbj.201301004 – volume: 9 start-page: 301 issue: 2 year: 2011 ident: 10.1016/j.schres.2017.09.021_bb0075 article-title: Oxidative stress in schizophrenia publication-title: Curr. Neuropharmacol. doi: 10.2174/157015911795596595 – volume: 6 issue: 7 year: 2009 ident: 10.1016/j.schres.2017.09.021_bb0360 article-title: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement publication-title: PLoS Med. doi: 10.1371/journal.pmed.1000097 – volume: 37 start-page: 1587 issue: 8 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0085 article-title: NMDA-receptor coagonists in serum, plasma, and cerebrospinal fluid of schizophrenia patients: a meta-analysis of case control studies publication-title: Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2013.06.007 – volume: 30 start-page: 357 issue: 4 year: 1991 ident: 10.1016/j.schres.2017.09.021_bb0235 article-title: Essential and other fatty acids in plasma in schizophrenics and normal individuals from Japan publication-title: Biol. Psychiatry doi: 10.1016/0006-3223(91)90291-S – volume: 6 start-page: 628 issue: 9 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0435 article-title: Functional metabolomics: from biomarker discovery to metabolome reprogramming publication-title: Protein Cell doi: 10.1007/s13238-015-0185-x – volume: 67 start-page: 146 issue: 2 year: 2010 ident: 10.1016/j.schres.2017.09.021_bb0025 article-title: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders a randomized, placebo-controlled trial publication-title: Arch. Gen. Psychiatry doi: 10.1001/archgenpsychiatry.2009.192 – volume: 42 start-page: 293 issue: 5 year: 2009 ident: 10.1016/j.schres.2017.09.021_bb0120 article-title: The diagnoses of schizophrenia, schizoaffective disorder, bipolar disorder and unipolar depression: interrater reliability and congruence between DSM-IV and ICD-10 publication-title: Psychopathology doi: 10.1159/000228838 – volume: 6 start-page: 102 issue: 1 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0285 article-title: Biomarkers in schizophrenia: a focus on blood based diagnostics and theranostics publication-title: World J. Psychiatry doi: 10.5498/wjp.v6.i1.102 – volume: 7 start-page: e42165 issue: 8 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb2000 article-title: Associations between purine metabolites and clinical symptoms in schizophrenia publication-title: PLoS One doi: 10.1371/journal.pone.0042165 – volume: 195 start-page: 579 issue: 4 year: 2008 ident: 10.1016/j.schres.2017.09.021_bb0215 article-title: 5-HT2A receptor density is decreased in the at-risk mental state publication-title: Psychopharmacology doi: 10.1007/s00213-007-0921-x – volume: 162 start-page: 1785 issue: 10 year: 2005 ident: 10.1016/j.schres.2017.09.021_bb0440 article-title: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.162.10.1785 – volume: 133 start-page: 77 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0060 article-title: Determination of steroid metabolome as a possible tool for laboratory diagnosis of schizophrenia publication-title: J. Steroid Biochem. Mol. Biol. doi: 10.1016/j.jsbmb.2012.08.009 – volume: 11 start-page: 851 year: 2008 ident: 10.1016/j.schres.2017.09.021_bb0390 article-title: Oxidative stress in psychiatric disorders: evidence base and therapeutic implications publication-title: IJNP – volume: 3 start-page: 117 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0370 article-title: Metabolomics of psychotic disorders publication-title: Metabolomics – volume: 44 start-page: 154 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0480 article-title: Sex differences in lipid peroxidation and fatty acid levels in recent onset schizophrenia publication-title: Prog. Neuro-Psychopharmacol. Biol. Psychiatry doi: 10.1016/j.pnpbp.2013.02.007 – volume: 3 issue: 3 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0150 article-title: Biomarkers of a five-domain translational substrate for schizophrenia and schizoaffective psychosis publication-title: Biomark. Res. – volume: 2 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb0190 article-title: Schizophrenia shows a unique metabolomics signature in plasma publication-title: Transl. Psychiatry doi: 10.1038/tp.2012.76 – volume: 45 start-page: 134 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0465 article-title: Clinically meaningful biomarkers for psychosis: a systematic and quantitative review publication-title: Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2014.05.010 – volume: 137 start-page: 174 issue: 2 year: 1980 ident: 10.1016/j.schres.2017.09.021_bb0055 article-title: CSF monoamine metabolites in depression and schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/ajp.137.2.174 – volume: 25 start-page: 468 issue: 4 year: 2001 ident: 10.1016/j.schres.2017.09.021_bb0510 article-title: The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients publication-title: Neuropsychopharmacology doi: 10.1016/S0893-133X(01)00250-0 – volume: 3 start-page: 93 issue: 5 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb0570 article-title: Peroxisomes, oxidative stress and inflammation publication-title: World J. Biol. Psychiatry – volume: 53 start-page: 56 issue: 1 year: 2003 ident: 10.1016/j.schres.2017.09.021_bb0035 article-title: Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients publication-title: Biol. Psychiatry doi: 10.1016/S0006-3223(02)01443-9 – volume: 40 start-page: 787 issue: 4 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0525 article-title: Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbt105 – volume: 173 start-page: 980 issue: 10 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0105 article-title: An individualized risk calculator for research in prodromal psychosis publication-title: Am. J. Psychiatry doi: 10.1176/appi.ajp.2016.15070890 – year: 2006 ident: 10.1016/j.schres.2017.09.021_bb0320 article-title: Phospholipids in schizophrenia – volume: 32 start-page: 1063 issue: 8 year: 1975 ident: 10.1016/j.schres.2017.09.021_bb0460 article-title: Cerebrospinal fluid amine metabolites in acute schizophrenia publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1975.01760260127011 – volume: 33 start-page: 21 issue: 1 year: 2007 ident: 10.1016/j.schres.2017.09.021_bb0080 article-title: Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbl049 – volume: 31 start-page: 3051 issue: 26 year: 1982 ident: 10.1016/j.schres.2017.09.021_bb0295 article-title: Red-cell phospholipids in schizophrenia publication-title: Life Sci. doi: 10.1016/0024-3205(82)90074-1 – volume: 176 start-page: 290 year: 2000 ident: 10.1016/j.schres.2017.09.021_bb0530 article-title: Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia publication-title: Brit. J. Psychiatry doi: 10.1192/bjp.176.3.290 – volume: 25 start-page: 389 issue: 4 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0270 article-title: Impact of different antipsychotics on cytokines and tryptophan metabolites in stimulated cultures from patients with schizophrenia publication-title: Psychiatr. Danub. – volume: 19 issue: 3 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0540 article-title: Omics-based biomarkers: application of metabolomics in neuropsychiatric disorders publication-title: Int. J. Neuropsychopharmacol. doi: 10.1093/ijnp/pyv096 – volume: 63 start-page: 262 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0115 article-title: Salivary cortisol in early psychosis: new findings and meta-analysis publication-title: Psychoneuroendocrinology doi: 10.1016/j.psyneuen.2015.10.007 – volume: 19 start-page: 45 issue: 1 year: 2007 ident: 10.1016/j.schres.2017.09.021_bb0395 article-title: Cerebrospinal fluid kynurenic acid in male patients with schizophrenia - correlation with monoamine metabolites publication-title: Acta Neuropsychiatr. doi: 10.1111/j.1601-5215.2006.00170.x – volume: 41 start-page: 1162 issue: 5 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0365 article-title: Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbv028 – volume: 143 start-page: 69 year: 1983 ident: 10.1016/j.schres.2017.09.021_bb0605 article-title: Plasma serine to cysteine ratio as a biological marker for psychosis publication-title: Brit. J. Psychiatry doi: 10.1192/bjp.143.1.69 – volume: 10 start-page: 431 issue: 4 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0180 article-title: The emergence of point-of-care blood-based biomarker testing for psychiatric disorders: enabling personalized medicine publication-title: Biomark. Med doi: 10.2217/bmm-2015-0055 – volume: 8 issue: 7 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0335 article-title: Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics publication-title: PLoS One doi: 10.1371/journal.pone.0068717 – year: 1999 ident: 10.1016/j.schres.2017.09.021_bb0200 – volume: 16 start-page: 441 issue: 6 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0505 article-title: Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls publication-title: World J. Biol. Psychiatry doi: 10.3109/15622975.2015.1048724 – volume: 124 start-page: 2209 issue: 11 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0040 article-title: Electrophysiological intermediate biomarkers for oxidative stress in schizophrenia publication-title: Clin. Neurophysiol. doi: 10.1016/j.clinph.2013.05.021 – volume: 18 start-page: 300 issue: 3 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0340 article-title: Meta-analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder publication-title: Bipolar Disord. doi: 10.1111/bdi.12386 – volume: 30 start-page: 193 issue: 3 year: 1998 ident: 10.1016/j.schres.2017.09.021_bb0195 article-title: The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia publication-title: Schizophr. Res. doi: 10.1016/S0920-9964(97)00151-5 – volume: 60 start-page: 163 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0280 article-title: Stress biomarkers as predictors of transition to psychosis in at-risk mental states: roles for cortisol, prolactin and albumin publication-title: J. Psychiatr. Res. doi: 10.1016/j.jpsychires.2014.10.011 – volume: 44 start-page: 604 issue: 7 year: 1987 ident: 10.1016/j.schres.2017.09.021_bb0240 article-title: Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. [Erratum appears in Arch Gen Psychiatry 1987 Oct; 44 (1):861] publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1987.01800190020003 – volume: 59 start-page: 123 issue: 2 year: 2009 ident: 10.1016/j.schres.2017.09.021_bb0255 article-title: Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients publication-title: Neuropsychobiology doi: 10.1159/000213565 – volume: 35 start-page: 165 issue: 2 year: 2009 ident: 10.1016/j.schres.2017.09.021_bb0475 article-title: Metabolomics tools for identifying biomarkers for neuropsychiatric diseases publication-title: Neurobiol. Dis. doi: 10.1016/j.nbd.2009.02.019 – volume: 6 start-page: 331 issue: 8 year: 1979 ident: 10.1016/j.schres.2017.09.021_bb0135 article-title: Urinary neurotransmitter metabolites in drug-free chronic-schizophrenic patients measured by gas-chromatography selected positive-ion monitoring publication-title: Biomed. Mass Spectrom. doi: 10.1002/bms.1200060804 – volume: 10 start-page: 5433 issue: 12 year: 2011 ident: 10.1016/j.schres.2017.09.021_bb0620 article-title: Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action publication-title: J. Proteome Res. doi: 10.1021/pr2006796 – volume: 6 start-page: e908 issue: 10 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0175 article-title: Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis publication-title: Transl. Psychiatry doi: 10.1038/tp.2016.159 – volume: 29 start-page: 138 issue: 2 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0455 article-title: Schizophrenia biomarkers: translating the descriptive into the diagnostic publication-title: J. Psychopharmacol. doi: 10.1177/0269881114566631 – volume: 21 start-page: 1024 issue: 11 year: 1986 ident: 10.1016/j.schres.2017.09.021_bb0330 article-title: Plasma prostaglandin E2 metabolite—measured as 11-deoxy-15-keto-13,14-dihydro-11 beta,16 xi-cyclo-PGE2—in twins with schizophrenic disorder publication-title: Biol. Psychiatry doi: 10.1016/0006-3223(86)90283-0 – volume: 11 start-page: 4338 issue: 8 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb0100 article-title: Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone publication-title: J. Proteome Res. doi: 10.1021/pr300459d – volume: 181 start-page: 363 year: 2002 ident: 10.1016/j.schres.2017.09.021_bb0130 article-title: Stress and the progression of the developmental hypothesis of schizophrenia publication-title: Brit. J. Psychiatry doi: 10.1192/bjp.181.5.363 – volume: 69 start-page: 661 issue: 11 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0160 article-title: Schizophrenia in 2020: trends in diagnosis and therapy publication-title: Psychiatry Clin. Neurosci. doi: 10.1111/pcn.12322 – volume: 43 start-page: 447 issue: 3 year: 1979 ident: 10.1016/j.schres.2017.09.021_bb0405 article-title: Fatty acid profiles in mental disease: part 1. Linoleate variations in schizophrenia publication-title: J. Neurol. Sci. doi: 10.1016/0022-510X(79)90023-6 – volume: 52 start-page: 823 issue: 8 year: 2002 ident: 10.1016/j.schres.2017.09.021_bb0630 article-title: Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites publication-title: Biol. Psychiatry doi: 10.1016/S0006-3223(02)01397-5 – volume: 43 start-page: 674 issue: 9 year: 1998 ident: 10.1016/j.schres.2017.09.021_bb0315 article-title: Elevated plasma lipid peroxides at the onset of nonaffective psychosis publication-title: Biol. Psychiatry doi: 10.1016/S0006-3223(97)00282-5 – volume: 5 start-page: 150 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0485 article-title: Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism publication-title: Front. Physiol. doi: 10.3389/fphys.2014.00150 – volume: 58 start-page: 1 issue: 1 year: 2002 ident: 10.1016/j.schres.2017.09.021_bb0245 article-title: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics publication-title: Schizophr. Res. doi: 10.1016/S0920-9964(01)00334-6 – volume: 18 start-page: 15 issue: 1 year: 1979 ident: 10.1016/j.schres.2017.09.021_bb0445 article-title: Dopamine, noradrenaline and serotonin spinal fluid metabolites in temporal lobe epileptic patients with schizophrenic symptomatology publication-title: Eur. Neurol. doi: 10.1159/000115048 – volume: 104 start-page: 36 issue: 1–3 year: 2008 ident: 10.1016/j.schres.2017.09.021_bb0300 article-title: Reduced plasma nitric oxide metabolites before and after antipsychotic treatment in patients with schizophrenia compared to controls publication-title: Schizophr. Res. doi: 10.1016/j.schres.2008.06.005 – volume: 10 start-page: 2398 issue: 9 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0305 article-title: GC-MS based metabolomics identification of possible novel biomarkers for schizophrenia in peripheral blood mononuclear cells publication-title: Mol. BioSyst. doi: 10.1039/C4MB00157E – volume: 32 start-page: 288 issue: 3 year: 1992 ident: 10.1016/j.schres.2017.09.021_bb0325 article-title: Biogenic-amine metabolites in plasma of drug-naive schizophrenic-patients - associations with symptomatology publication-title: Biol. Psychiatry doi: 10.1016/0006-3223(92)90110-L – volume: 56 start-page: 774 issue: 6–7 year: 2010 ident: 10.1016/j.schres.2017.09.021_bb0655 article-title: Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients publication-title: Neurochem. Int. doi: 10.1016/j.neuint.2010.02.015 – volume: 33 start-page: 712 issue: 12 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0110 article-title: Commercialisation of biomarker tests for mental illnesses: advances one obstacles publication-title: Trends Biotechnol. doi: 10.1016/j.tibtech.2015.09.010 – volume: 176 start-page: 52 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0260 article-title: Implications for reactive species in schizophrenia pathogenesis publication-title: Schizophr. Res. doi: 10.1016/j.schres.2015.06.022 – volume: 6 start-page: 1 issue: 1 year: 1991 ident: 10.1016/j.schres.2017.09.021_bb0045 article-title: Fatty acids in plasma phospholipids and cholesterol esters from identical twins concordant and discordant with schizophrenia publication-title: Schizophr. Res. doi: 10.1016/0920-9964(91)90014-I – volume: 13 start-page: 195 issue: 3 year: 1994 ident: 10.1016/j.schres.2017.09.021_bb0210 article-title: The membrane hypothesis of schizophrenia publication-title: Schizophr. Res. doi: 10.1016/0920-9964(94)90043-4 – volume: 13 start-page: 226 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0310 article-title: Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study publication-title: J. Transl. Med. doi: 10.1186/s12967-015-0540-y – volume: 35 start-page: 401 issue: 5 year: 2004 ident: 10.1016/j.schres.2017.09.021_bb0565 article-title: Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia publication-title: Arch. Med. Res. doi: 10.1016/j.arcmed.2004.06.002 – volume: 16 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0145 article-title: Differential expression of the inflammation marker IL12p40 in the at-risk mental state for psychosis: a predictor of transition to psychotic disorder? publication-title: BMC Psychiatry doi: 10.1186/s12888-016-1039-7 – volume: 44 start-page: 212 issue: 3 year: 2002 ident: 10.1016/j.schres.2017.09.021_bb0030 article-title: CSF amines and their metabolites in first episode drug naive schizophrenic patients and their correlations with dimensions of schizophrenia publication-title: Indian J. Psychiatry – volume: 5 start-page: 756 issue: 4 year: 2006 ident: 10.1016/j.schres.2017.09.021_bb0575 article-title: Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients publication-title: J. Proteome Res. doi: 10.1021/pr0503782 – volume: 12 start-page: 53 issue: 1 year: 1994 ident: 10.1016/j.schres.2017.09.021_bb0170 article-title: A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases publication-title: Schizophr. Res. doi: 10.1016/0920-9964(94)90084-1 – volume: 147 start-page: 276 issue: SEP year: 1985 ident: 10.1016/j.schres.2017.09.021_bb0065 article-title: Plasma amino-acids in relation to cerebrospinal-fluid monoamine metabolites in schizophrenic-patients and healthy controls publication-title: Brit. J. Psychiatry doi: 10.1192/bjp.147.3.276 – volume: 93 start-page: 23 issue: 1 year: 2011 ident: 10.1016/j.schres.2017.09.021_bb0090 article-title: The environment and susceptibility to schizophrenia publication-title: Prog. Neurobiol. doi: 10.1016/j.pneurobio.2010.09.003 – volume: 66 start-page: 350 issue: 5 year: 1982 ident: 10.1016/j.schres.2017.09.021_bb0165 article-title: CSF monoamine metabolites in schizophrenic-patients publication-title: Acta Psychiatr. Scand. doi: 10.1111/j.1600-0447.1982.tb06717.x – volume: 153 start-page: 203 issue: 2 year: 2007 ident: 10.1016/j.schres.2017.09.021_bb0640 article-title: Increased urinary excretion of biopyrrins, oxidative metabolites of bilirubin, in patients with schizophrenia publication-title: Psychiatry Res. doi: 10.1016/j.psychres.2006.04.009 – volume: 13 start-page: 1141 issue: 12 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0495 article-title: Blood biomarker discovery in drug-free schizophrenia: the contribution of proteomics and multiplex immunoassays publication-title: Expert Rev. Proteomics doi: 10.1080/14789450.2016.1252262 – volume: 41 start-page: 1461 issue: 7 year: 2011 ident: 10.1016/j.schres.2017.09.021_bb0290 article-title: Early detection of psychosis: positive effects on 5-year outcome publication-title: Psychol. Med. doi: 10.1017/S0033291710002023 – year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0015 – volume: 9 start-page: 301 issue: 4 year: 1983 ident: 10.1016/j.schres.2017.09.021_bb0400 article-title: Cerebroventricular size and cerebrospinal-fluid monoamine metabolites in schizophrenic-patients and healthy-volunteers publication-title: Psychiatry Res. doi: 10.1016/0165-1781(83)90003-3 – volume: 14 start-page: 93 issue: 2 year: 1995 ident: 10.1016/j.schres.2017.09.021_bb0470 article-title: Histamine metabolites in cerebrospinal-fluid of patients with chronic-schizophrenia - their relationships to levels of other aminergic transmitters and ratings of symptoms publication-title: Schizophr. Res. doi: 10.1016/0920-9964(94)00034-6 – volume: 70 start-page: 133 issue: 3 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0555 article-title: Peripheral glutamate levels in schizophrenia: evidence from a meta-analysis publication-title: Neuropsychobiology doi: 10.1159/000364828 – volume: 39 start-page: 24 issue: 1 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0615 article-title: Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology publication-title: Neuropsychopharmacology doi: 10.1038/npp.2013.167 – volume: 25 start-page: 562 issue: 5 year: 1989 ident: 10.1016/j.schres.2017.09.021_bb0205 article-title: Essential fatty acids in plasma phospholipids in schizophrenics publication-title: Biol. Psychiatry doi: 10.1016/0006-3223(89)90216-3 – volume: 3 start-page: 19 year: 2011 ident: 10.1016/j.schres.2017.09.021_bb0415 article-title: Metabolome in schizophrenia and other psychotic disorders: a general population-based study publication-title: Genome Med. doi: 10.1186/gm233 – volume: 12 start-page: 934 issue: 10 year: 2007 ident: 10.1016/j.schres.2017.09.021_bb0225 article-title: Metabolomic mapping of atypical antipsychotic effects in schizophrenia publication-title: Mol. Psychiatry doi: 10.1038/sj.mp.4002000 – volume: 17 start-page: 494 issue: 5 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb0520 article-title: Identification of a biological signature for schizophrenia in serum publication-title: Mol. Psychiatry doi: 10.1038/mp.2011.42 – volume: 164 start-page: 1072 issue: 7 year: 2007 ident: 10.1016/j.schres.2017.09.021_bb0095 article-title: Relative glucose metabolic rate higher in white matter in patients with schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/ajp.2007.164.7.1072 – volume: 99 start-page: 322 issue: 3 year: 1989 ident: 10.1016/j.schres.2017.09.021_bb0010 article-title: Monoamine metabolites and amino-acids in serum from schizophrenic-patients before and during sulpiride treatment publication-title: Psychopharmacology doi: 10.1007/BF00445551 – volume: 40 start-page: 963 issue: 5 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0185 article-title: Inflammatory molecular signature associated with infectious agents in psychosis publication-title: Schizophr. Bull. doi: 10.1093/schbul/sbu052 – volume: 135 start-page: 567 issue: 5 year: 1978 ident: 10.1016/j.schres.2017.09.021_bb0585 article-title: MAO activity, CSF amine metabolites, and drug-free improvement in schizophrenia publication-title: Am. J. Psychiatry doi: 10.1176/ajp.135.5.567 – volume: 20 start-page: 171 issue: 2 year: 2002 ident: 10.1016/j.schres.2017.09.021_bb0275 article-title: Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder publication-title: Cell Biochem. Funct. doi: 10.1002/cbf.940 – volume: 23 start-page: D112 issue: 1 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0350 article-title: Phospholipid, arachidonate and eicosanoid signaling in schizophrenia publication-title: OCL doi: 10.1051/ocl/2015054 – volume: 18 start-page: 576 issue: 4 year: 2012 ident: 10.1016/j.schres.2017.09.021_bb0375 article-title: Polyunsaturated fatty acids in emerging psychosis publication-title: Curr. Pharm. Des. doi: 10.2174/138161212799316055 – volume: 132 start-page: 293 issue: 4 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0550 article-title: Association between serum lipids and membrane fatty acids and clinical characteristics in patients with schizophrenia publication-title: Acta Psychiatr. Scand. doi: 10.1111/acps.12388 – volume: 50 start-page: 599 issue: 8 year: 1993 ident: 10.1016/j.schres.2017.09.021_bb0230 article-title: Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Serotonin-dopamine interactions as a target for treatment publication-title: Arch. Gen. Psychiatry doi: 10.1001/archpsyc.1993.01820200009001 – volume: 29 start-page: 199 issue: 2 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0355 article-title: Switching antipsychotics to aripiprazole or blonanserin and plasma monoamine metabolites levels in patients with schizophrenia publication-title: Hum. Psychopharmacol. doi: 10.1002/hup.2386 – volume: 18 start-page: 67 issue: 1 year: 2013 ident: 10.1016/j.schres.2017.09.021_bb0625 article-title: Potential metabolite markers of schizophrenia publication-title: Mol. Psychiatry doi: 10.1038/mp.2011.131 – volume: 122 start-page: S111 issue: Suppl. 1 year: 2015 ident: 10.1016/j.schres.2017.09.021_bb0005 article-title: Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia publication-title: J. Neural Transm. doi: 10.1007/s00702-014-1224-0 – volume: 71 start-page: 1121 issue: 10 year: 2014 ident: 10.1016/j.schres.2017.09.021_bb0250 article-title: Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2014.1332 – volume: 11 issue: 5 year: 2016 ident: 10.1016/j.schres.2017.09.021_bb0425 article-title: Omega-3 and Omega-6 polyunsaturated fatty acid levels and correlations with symptoms in children with attention deficit hyperactivity disorder, autistic Spectrum disorder and typically developing controls publication-title: PLoS One doi: 10.1371/journal.pone.0156432 |
| SSID | ssj0001507 |
| Score | 2.5832546 |
| SecondaryResourceType | review_article |
| Snippet | Current diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more... AbstractCurrent diagnosis of schizophrenia relies exclusively on the potentially subjective interpretation of clinical symptoms and social functioning as more... |
| SourceID | unpaywall proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 32 |
| SubjectTerms | Biofluid Biomarkers Biomarkers - metabolism Databases, Bibliographic - statistics & numerical data Fatty Acids, Unsaturated - metabolism Humans Lipid Peroxidation - physiology Lipidomics Metabolomics Metabolomics - methods Psychiatric/Mental Health Psychosis Schizophrenia Schizophrenia - diagnosis Schizophrenia - metabolism Vitamin E - metabolism |
| SummonAdditionalLinks | – databaseName: Elsevier SD Freedom Collection dbid: .~1 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF6KF_Ugiq_6IoLXtNnsbrI5eCjFUgS9aKG3ZbPZhUpNS5MiXvztzubRVqq0eMghj8kmk29mZ8h8swjdAUgYxQBezzfMpSHBrlQ6dJViQRxqwIy0f3SfnoP-gD4O2bCBujUXxpZVVr6_9OmFt66OtCtttqejUfvFiyztM6AYQMp4wSinNLSrGLS-lmUeNuAp-u1BmmSvrulzRY0XJJCQ1NoCr7Dodurjv6an9fBzH-3O06n8_JDj8cqU1DtEB1Us6XTKxz1CDZ0eo_uOs-zO7JTMFGdinHedw_e2jGPHUu5tVc4ssyey1bK7EzToPbx2-261RoKrGPdzl8SRijVlEYuUlrBRZmKGAx3LgBGPa6YoZx5VXFIpdZIE1PgSjNKykSG3I6doJ52k-hw5mhvJSIIVBIU05EFs7M0NMTB_4QSHTURq1QhVNRC361iMRV0p9iZKhQqrUOFFAhTaRO5Calo20NhwPau1LmpyKLgzAR5-g1z4m5zOKpvMBBaZLzyxhptVyR_Q22LM2xoWAqzS_mqRqZ7MYayIEgjcIPZrorMSL4u3hxQXbIKCdGsBoK1Uc_HvB71Ee7DHy0LNK7STz-b6GoKpPL4prOUbP_gbmQ priority: 102 providerName: Elsevier |
| Title | A systematic review of metabolite biomarkers of schizophrenia |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0920996417305807 https://www.clinicalkey.es/playcontent/1-s2.0-S0920996417305807 https://dx.doi.org/10.1016/j.schres.2017.09.021 https://www.ncbi.nlm.nih.gov/pubmed/28947341 https://www.proquest.com/docview/1943283937 http://hdl.handle.net/10197/9339 |
| UnpaywallVersion | submittedVersion |
| Volume | 195 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier) customDbUrl: eissn: 1573-2509 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001507 issn: 1573-2509 databaseCode: GBLVA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Complete Freedom Collection [SCCMFC] customDbUrl: eissn: 1573-2509 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001507 issn: 1573-2509 databaseCode: ACRLP dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection customDbUrl: eissn: 1573-2509 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001507 issn: 1573-2509 databaseCode: .~1 dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVESC databaseName: ScienceDirect Journal Collection customDbUrl: eissn: 1573-2509 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001507 issn: 1573-2509 databaseCode: AIKHN dateStart: 19950101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1573-2509 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001507 issn: 1573-2509 databaseCode: AKRWK dateStart: 19880101 isFulltext: true providerName: Library Specific Holdings |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Nj9MwEB112wPLYQHBQlmogsQ1JY49cXLYQ7ViVUBbrQSVyslyXOcAJV1tUq2WA7-dcT5KRalaDjlEySSy543njTwzBnhLIEHBCLxBmKEvJGe-Nlb6xmCUSkuY0W5H92oSjafi4wxnHWiPrPurvQDhJZHvKOZOjqAXIbHtLvSmk-vR16qFHkU-RNerjWOU3CdvnrTVcVUKF8WHFLO6_C1ZNTMN2S7vs80uH8KDVX6j7-_0YrHhcS4f1ZmPRdWo0CWafB-uynRofm63cdw5mMdw0tBNb1Tj4wl0bP4UzkfenwbOXl284i0z74ctCRKuKNlzVfkucee2cA-Kzcy8ZzC9fP_lYuw3xyj4BuOw9HmamNQKTDAxVtMlMEuRRTbVEfIgtmhEjIEwsRZa2_k8ElmoyW5dwTKFf_wUuvkyty_As3Gmkc-ZId4oZBylmft4xjNycWzOZB94O73KND3G3VEXC9Umk31TtVKUU4oKEkVK6YO_lrqpe2zseR9bzam2fpRWPEVOYI-c_JecLRqzLRRTRagC9dlByyGL0fqHcSA3JRtmUjOOA_75poWWIsN1uzE6t8sV_SsRnLgd0cM-PK8xtx49RcFkNoKkh2sQHjQ1L_9X4AyO6S6uUzhfQbe8XdnXRLPKdABHw19sAL3Rh0_jyaCxu9-mDSUU |
| linkProvider | Unpaywall |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV07T8MwELYqGIABgXiVZ5BY08axHScDQ4WoynOBSt0sx3UkUEmrphVi4bdzl0cpAkTFkCXOJc7lu_Odct-ZkDMAieAUwOv5iXC5ZNTVxkrXGBHE0gJmNP7RvbsPOl1-3RO9GrmouDBYVln6_sKn5966PNMstdkcPT01H7wIaZ8BpwBSESKjfJkLX2IG1nj_rPPAiCdvuAd5El5e8efyIi_IICGrxQovmbc79elv69P3-HONrEzTkX571YPB3JrU3iDrZTDptIr5bpKaTbfIecv5bM_sFNQUZ5g4L3YCHxwpxw5y7rEsZ5zhQDZfd7dNuu3Lx4uOW26S4BoR-hOXxZGJLReRiIzVcHCRxIIGNtaBYF5oheGh8LgJNdfa9vsBT3wNVol0ZEju2A5ZSoep3SOODRMtWJ8aiAq5DIM4wZsnLIEFjPaprBNWqUaZsoM4bmQxUFWp2LMqFKpQocqLFCi0TtyZ1KjooPHH9aLSuqrYoeDPFLj4P-TkT3I2K40yU1RlvvLUN-DMS37B3gLPPK1gocAs8V-LTu1wCs-KOIPIDYK_Otkt8DJ7e8hxwSg4SDdmAFpINfv_nugJWek83t2q26v7mwOyCiNhUbV5SJYm46k9gshqEh_nlvMBiPUevA |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9tAEB6FcIAeWhCvtBQZiauD17vjtQ89RBUIVSqqBJHCabXerA8QnAg7quDXd9aPNIJGpAcfLHts7c43O99oZ2YBzggkKBiBNwgz9IXkzNfGSt8YjFJpCTPa7ej-vI6uhuLHCEcdaI-se9VegPCSyHOKuZMN2IyQ2HYXNofXvwZ3VQs9inyIrlcbxyi5T948aavjqhQuig8pZnX5W7JqZhqyVd7nLbv8AFvzfKaff-vJZMnjXH6qMx-LqlGhSzR56M_LtG9e3rZxXDmYHfjY0E1vUONjFzo234NvA-9vA2evLl7xppn3aEuChCtK9lxVvkvceSrcg2I5M28fhpcXt9-v_OYYBd9gHJY-TxOTWoEJJsZqugRmKbLIpjpCHsQWjYgxECbWQms7HkciCzXZrStYpvCPH0A3n-b2CDwbZxr5mBnijULGUZq5j2c8IxfHxkz2gLfTq0zTY9wddTFRbTLZvaqVopxSVJAoUkoP_IXUrO6x8c772GpOtfWjtOIpcgLvyMl_ydmiMdtCMVWEKlA3DloOWYzWP4wDuSzZMJOacazxz9MWWooM1-3G6NxO5_SvRHDidkQPe3BYY24xeoqCyWwESfcXIFxraj7_r8AX2Ka7uE7hPIZu-TS3X4lmlelJY2l_ALYiIog |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+systematic+review+of+metabolite+biomarkers+of+schizophrenia&rft.jtitle=Schizophrenia+research&rft.au=Davison%2C+Jennifer&rft.au=O%27Gorman%2C+Aoife&rft.au=Brennan%2C+Lorraine&rft.au=Cotter%2C+David+R&rft.date=2018-05-01&rft.issn=0920-9964&rft.volume=195&rft.spage=32&rft.epage=50&rft_id=info:doi/10.1016%2Fj.schres.2017.09.021&rft.externalDBID=ECK1-s2.0-S0920996417305807&rft.externalDocID=1_s2_0_S0920996417305807 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F09209964%2FS0920996418X0005X%2Fcov150h.gif |